|
Empagliflozin after Acute Myocardial Infarction.
|
N Engl J Med
38587237
|
0 |
158.5 |
2024 |
|
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
|
Circulation
38581389
|
0 |
37.8 |
2024 |
|
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
|
Circulation
38583093
|
0 |
37.8 |
2024 |
|
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
|
J Am Coll Cardiol
38588929
|
0 |
24 |
2024 |
|
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.
|
Eur J Heart Fail
38439585
|
0 |
18.2 |
2024 |
|
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
|
Eur J Heart Fail
38247160
|
0 |
18.2 |
2024 |
|
Impact of anaemia and iron deficiency on outcomes in cardiogenic shock complicating acute myocardial infarction.
|
Eur J Heart Fail
38084483
|
0 |
18.2 |
2024 |
|
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme.
|
Eur J Heart Fail
38439582
|
0 |
18.2 |
2024 |
|
Neuromodulation interventions in the management of heart failure.
|
Eur J Heart Fail
38247193
|
0 |
18.2 |
2024 |
|
Transcatheter aortic valve replacement in heart failure.
|
Eur J Heart Fail
38297972
|
0 |
18.2 |
2024 |
|
The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
|
Eur J Heart Fail
38235936
|
0 |
18.2 |
2024 |
|
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.
|
Eur J Heart Fail
38269451
|
0 |
18.2 |
2024 |
|
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme.
|
Eur J Heart Fail
38587259
|
0 |
18.2 |
2024 |
|
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
|
Eur J Heart Fail
38269474
|
0 |
18.2 |
2024 |
|
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.
|
Eur J Heart Fail
38131233
|
0 |
18.2 |
2024 |
|
Interatrial shunt therapy in advanced heart failure: Outcomes from the open-label cohort of the RELIEVE-HF trial.
|
Eur J Heart Fail
38561314
|
0 |
18.2 |
2024 |
|
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.
|
Eur J Heart Fail
38558521
|
0 |
18.2 |
2024 |
|
Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.
|
J Cachexia Sarcopenia Muscle
38561962
|
0 |
8.9 |
2024 |
|
The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications.
|
J Cachexia Sarcopenia Muscle
38291000
|
0 |
8.9 |
2024 |
|
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
|
Diabetes Obes Metab
38558314
|
0 |
5.8 |
2024 |
|
Association of an impaired GH-IGF-I axis with cardiac wasting in patients with advanced cancer.
|
Clin Res Cardiol
38587563
|
0 |
5 |
2024 |
|
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
|
BMJ Open
38508632
|
0 |
2.9 |
2024 |
|
Thinner is better: Intentional weight loss and cardiovascular risk.
|
Med
38614070
|
0 |
0 |
2024 |
|
Increased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction.
|
J Clin Med
38337428
|
0 |
0 |
2024 |
|
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
|
N Engl J Med
38048198
|
0 |
158.5 |
2023 |
|
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
|
Lancet Diabetes Endocrinol
37996192
|
0 |
44.5 |
2023 |
|
Iron deficiency as a promoter of cardiotoxicity: not only cadmium-induced.
|
Eur Heart J
37204931
|
0 |
39.3 |
2023 |
|
The cardiovascular effects of novel weight loss therapies.
|
Eur Heart J
37966486
|
1 |
39.3 |
2023 |
|
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
|
Eur Heart J
37632415
|
0 |
39.3 |
2023 |
|
Carat, clarity, colour, and cut: grading the DIAMOND trial.
|
Eur Heart J
37583291
|
0 |
39.3 |
2023 |
|
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials.
|
Eur Heart J
37098746
|
1 |
39.3 |
2023 |
|
Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
|
Eur Heart J
36879413
|
0 |
39.3 |
2023 |
|
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table.
|
Eur Heart J
37448181
|
1 |
39.3 |
2023 |
|
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
|
Ann Intern Med
38048573
|
2 |
39.2 |
2023 |
|
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
|
Circulation
37051919
|
3 |
37.8 |
2023 |
|
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
|
Circulation
37621153
|
0 |
37.8 |
2023 |
|
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
|
J Am Coll Cardiol
36653095
|
8 |
24 |
2023 |
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
J Am Coll Cardiol
37344038
|
5 |
24 |
2023 |
|
Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review.
|
J Am Coll Cardiol
37758440
|
1 |
24 |
2023 |
|
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
|
JAMA Cardiol
37223933
|
1 |
24 |
2023 |
|
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer.
|
J Am Coll Cardiol
37076211
|
3 |
24 |
2023 |
|
Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure.
|
J Am Coll Cardiol
37940229
|
0 |
24 |
2023 |
|
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
|
J Am Coll Cardiol
37164523
|
0 |
24 |
2023 |
|
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
|
JAMA Cardiol
37314801
|
3 |
24 |
2023 |
|
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
|
Kidney Int
37236424
|
5 |
19.6 |
2023 |
|
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.
|
Eur J Heart Fail
37461163
|
3 |
18.2 |
2023 |
|
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials.
|
Eur J Heart Fail
38037709
|
0 |
18.2 |
2023 |
|
Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the VECTOR-HF trial.
|
Eur J Heart Fail
37092287
|
2 |
18.2 |
2023 |
|
Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry.
|
Eur J Heart Fail
37365841
|
0 |
18.2 |
2023 |
|
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
|
Eur J Heart Fail
37062866
|
0 |
18.2 |
2023 |
|
Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
|
Eur J Heart Fail
37312239
|
1 |
18.2 |
2023 |
|
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.
|
Eur J Heart Fail
37062851
|
4 |
18.2 |
2023 |
|
Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery.
|
Eur J Heart Fail
37990135
|
0 |
18.2 |
2023 |
|
Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
|
Eur J Heart Fail
37062867
|
4 |
18.2 |
2023 |
|
Sodium-glucose cotransporter 2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: Any incremental effect?
|
Eur J Heart Fail
37846611
|
0 |
18.2 |
2023 |
|
Health status across major subgroups of patients with heart failure and preserved ejection fraction.
|
Eur J Heart Fail
36974746
|
0 |
18.2 |
2023 |
|
Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
|
Eur J Heart Fail
37369985
|
0 |
18.2 |
2023 |
|
Little at a time: trying to understand the battery of benefits of sodium-glucose contransporter 2 inhibitors in heart failure.
|
Eur J Heart Fail
36597825
|
0 |
18.2 |
2023 |
|
Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
|
Eur J Heart Fail
37098791
|
1 |
18.2 |
2023 |
|
Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC.
|
Eur J Heart Fail
37448210
|
1 |
18.2 |
2023 |
|
The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia.
|
Eur J Heart Fail
36999379
|
3 |
18.2 |
2023 |
|
Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome.
|
Eur J Heart Fail
36597718
|
0 |
18.2 |
2023 |
|
Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
|
Eur J Heart Fail
36781201
|
0 |
18.2 |
2023 |
|
Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure.
|
Eur J Heart Fail
37038319
|
0 |
18.2 |
2023 |
|
Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry.
|
Eur J Heart Fail
37661847
|
1 |
18.2 |
2023 |
|
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial.
|
Eur J Heart Fail
37278451
|
0 |
18.2 |
2023 |
|
Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure.
|
Eur J Heart Fail
37062865
|
1 |
18.2 |
2023 |
|
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
37208936
|
5 |
18.2 |
2023 |
|
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program.
|
Eur J Heart Fail
37964408
|
0 |
18.2 |
2023 |
|
Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC-HFA EORP Heart Failure Long-Term Registry.
|
Eur J Heart Fail
37114294
|
1 |
18.2 |
2023 |
|
Baseline characteristics of patients enrolled in the EMPACT-MI trial.
|
Eur J Heart Fail
37622416
|
0 |
18.2 |
2023 |
|
Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry.
|
Eur J Heart Fail
37210639
|
0 |
18.2 |
2023 |
|
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance.
|
Diabetes Care
38151465
|
0 |
16.2 |
2023 |
|
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
|
Diabetes Care
37310695
|
0 |
16.2 |
2023 |
|
Metabolic dysfunction-associated steatotic liver disease and the heart.
|
Hepatology
38147315
|
1 |
13.5 |
2023 |
|
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.
|
JACC Heart Fail
36881400
|
1 |
13 |
2023 |
|
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.
|
JACC Heart Fail
37715769
|
0 |
13 |
2023 |
|
Medication-Attributable Adverse Events in Heart Failure Trials.
|
JACC Heart Fail
36881395
|
0 |
13 |
2023 |
|
Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?
|
JACC Heart Fail
37943226
|
0 |
13 |
2023 |
|
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis.
|
JACC Heart Fail
36872213
|
0 |
13 |
2023 |
|
Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure.
|
Cardiovasc Res
36883593
|
0 |
10.8 |
2023 |
|
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
|
Clin J Am Soc Nephrol
37382961
|
1 |
10.624 |
2023 |
|
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
|
Clin J Am Soc Nephrol
36927680
|
3 |
10.624 |
2023 |
|
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
|
Cardiovasc Diabetol
37592272
|
0 |
9.3 |
2023 |
|
Anorexia of aging: An international assessment of healthcare providers' knowledge and practice gaps.
|
J Cachexia Sarcopenia Muscle
37897129
|
2 |
8.9 |
2023 |
|
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
|
J Cachexia Sarcopenia Muscle
38158636
|
1 |
8.9 |
2023 |
|
Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer.
|
J Cachexia Sarcopenia Muscle
37222009
|
2 |
8.9 |
2023 |
|
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.
|
J Cachexia Sarcopenia Muscle
37671529
|
3 |
8.9 |
2023 |
|
Hand grip strength in patients with advanced cancer: A prospective study.
|
J Cachexia Sarcopenia Muscle
37318103
|
3 |
8.9 |
2023 |
|
Kidney function in cachexia and sarcopenia: Facts and numbers.
|
J Cachexia Sarcopenia Muscle
37222019
|
0 |
8.9 |
2023 |
|
The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey.
|
J Cachexia Sarcopenia Muscle
38018293
|
2 |
8.9 |
2023 |
|
Frailty and heart failure: State-of-the-art review.
|
J Cachexia Sarcopenia Muscle
37586848
|
2 |
8.9 |
2023 |
|
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: Update 2023.
|
J Cachexia Sarcopenia Muscle
38148513
|
0 |
8.9 |
2023 |
|
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.
|
Arterioscler Thromb Vasc Biol
37199158
|
1 |
8.7 |
2023 |
|
Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry.
|
Eur J Prev Cardiol
37172316
|
2 |
8.3 |
2023 |
|
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.
|
Diabetologia
38127122
|
0 |
8.2 |
2023 |
|
SGLT2-inhibitors: Should they be considered anti-remodeling drugs?
|
Eur J Intern Med
37225594
|
0 |
8 |
2023 |
|
Overcoming barriers to timely recognition and treatment of cancer cachexia: Sharing Progress in Cancer Care Task Force Position Paper and Call to Action.
|
Crit Rev Oncol Hematol
36931616
|
1 |
6.2 |
2023 |
|
EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
|
Europace
37061780
|
10 |
6.1 |
2023 |
|
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.
|
J Card Fail
37558088
|
0 |
6 |
2023 |
|
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
|
J Card Fail
38122924
|
0 |
6 |
2023 |
|
Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
|
J Card Fail
37117140
|
4 |
6 |
2023 |
|
A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.
|
United European Gastroenterol J
37563849
|
1 |
6 |
2023 |
|
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
|
Diabetes Obes Metab
37402696
|
2 |
5.8 |
2023 |
|
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
|
Diabetes Obes Metab
36722675
|
1 |
5.8 |
2023 |
|
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
|
Diabetes Obes Metab
37814928
|
0 |
5.8 |
2023 |
|
Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure.
|
Clin Res Cardiol
36997667
|
1 |
5 |
2023 |
|
The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies.
|
Clin Res Cardiol
36884078
|
2 |
5 |
2023 |
|
Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial.
|
Clin Res Cardiol
37407731
|
0 |
5 |
2023 |
|
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
|
Eur Heart J Cardiovasc Pharmacother
36639130
|
3 |
4.841 |
2023 |
|
Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure.
|
Am Heart J
37972677
|
0 |
4.8 |
2023 |
|
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
|
Am J Physiol Heart Circ Physiol
38133623
|
1 |
4.8 |
2023 |
|
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
|
Am J Nephrol
37708857
|
0 |
4.2 |
2023 |
|
Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction.
|
ESC Heart Fail
37312287
|
0 |
3.8 |
2023 |
|
Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D.
|
Int J Cardiol
37739044
|
0 |
3.5 |
2023 |
|
Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF.
|
Int J Cardiol
38141725
|
0 |
3.5 |
2023 |
|
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction.
|
J Cardiovasc Transl Res
36795286
|
0 |
3.4 |
2023 |
|
Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes.
|
J Nephrol
36995528
|
0 |
3.4 |
2023 |
|
Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
|
BMJ Open
37567750
|
0 |
2.9 |
2023 |
|
Heart Failure Hospitalizations Versus Cardiovascular Mortality in Heart Failure Trials.
|
Am J Cardiol
37558550
|
0 |
2.8 |
2023 |
|
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
|
Kidney Med
38046911
|
0 |
2.317 |
2023 |
|
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
|
Kidney Med
37745646
|
0 |
2.317 |
2023 |
|
Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis.
|
Arch Ital Urol Androl
37314421
|
0 |
0.01 |
2023 |
|
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence.
|
Int J Heart Fail
37180562
|
3 |
0.01 |
2023 |
|
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
|
Lancet
36351458
|
73 |
168.9 |
2022 |
|
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply.
|
N Engl J Med
35613034
|
2 |
158.5 |
2022 |
|
Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project).
|
BMJ
35545258
|
39 |
105.7 |
2022 |
|
CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.
|
BMJ
36562446
|
4 |
105.7 |
2022 |
|
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
|
Nat Med
36471037
|
0 |
82.9 |
2022 |
|
The need for increased pragmatism in cardiovascular clinical trials.
|
Nat Rev Cardiol
35581337
|
8 |
49.6 |
2022 |
|
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
|
Eur Heart J
35788657
|
9 |
39.3 |
2022 |
|
Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure.
|
Eur Heart J
36036745
|
1 |
39.3 |
2022 |
|
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
|
Eur Heart J
35687107
|
6 |
39.3 |
2022 |
|
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
|
Eur Heart J
34878502
|
37 |
39.3 |
2022 |
|
Albuminuria as a marker of systemic congestion in patients with heart failure.
|
Eur Heart J
36148485
|
6 |
39.3 |
2022 |
|
Kidney function assessment and endpoint ascertainment in clinical trials.
|
Eur Heart J
34966917
|
2 |
39.3 |
2022 |
|
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
|
Eur Heart J
35900838
|
20 |
39.3 |
2022 |
|
Iron deficiency and cardiovascular disease.
|
Eur Heart J
36282723
|
15 |
39.3 |
2022 |
|
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.
|
Eur Heart J
36017745
|
22 |
39.3 |
2022 |
|
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
|
Eur Heart J
36478225
|
1 |
39.3 |
2022 |
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
|
Eur Heart J
35023547
|
103 |
39.3 |
2022 |
|
CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.
|
Eur Heart J
36208161
|
8 |
39.3 |
2022 |
|
'Normal weight' is really not normal in chronic disease.
|
Eur Heart J
36029317
|
1 |
39.3 |
2022 |
|
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
|
Circulation
36098051
|
4 |
37.8 |
2022 |
|
SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
|
Circulation
35877834
|
2 |
37.8 |
2022 |
|
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
|
Circulation
36342827
|
1 |
37.8 |
2022 |
|
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
|
Circulation
35762322
|
21 |
37.8 |
2022 |
|
CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.
|
Lancet Digit Health
36050271
|
6 |
30.8 |
2022 |
|
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
|
JAMA Cardiol
36129693
|
5 |
24 |
2022 |
|
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.
|
JAMA Cardiol
36334258
|
3 |
24 |
2022 |
|
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
|
J Am Coll Cardiol
35331406
|
8 |
24 |
2022 |
|
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.
|
J Am Coll Cardiol
35589167
|
18 |
24 |
2022 |
|
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
|
J Am Coll Cardiol
35772911
|
3 |
24 |
2022 |
|
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
|
JAMA Cardiol
36044233
|
3 |
24 |
2022 |
|
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
|
Kidney Int
36367466
|
6 |
19.6 |
2022 |
|
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.
|
Eur J Heart Fail
34894038
|
18 |
18.2 |
2022 |
|
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
|
Eur J Heart Fail
35796209
|
6 |
18.2 |
2022 |
|
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.
|
Eur J Heart Fail
34989084
|
2 |
18.2 |
2022 |
|
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
|
Eur J Heart Fail
35293087
|
4 |
18.2 |
2022 |
|
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
|
Eur J Heart Fail
35869741
|
4 |
18.2 |
2022 |
|
Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
35334137
|
7 |
18.2 |
2022 |
|
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.
|
Eur J Heart Fail
34962044
|
11 |
18.2 |
2022 |
|
Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis.
|
Eur J Heart Fail
35730422
|
1 |
18.2 |
2022 |
|
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.
|
Eur J Heart Fail
34989083
|
8 |
18.2 |
2022 |
|
Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
35014132
|
0 |
18.2 |
2022 |
|
A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential.
|
Eur J Heart Fail
34969173
|
4 |
18.2 |
2022 |
|
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
|
Eur J Heart Fail
35753058
|
5 |
18.2 |
2022 |
|
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology.
|
Eur J Heart Fail
36039656
|
12 |
18.2 |
2022 |
|
Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial.
|
Eur J Heart Fail
36088540
|
0 |
18.2 |
2022 |
|
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
|
Eur J Heart Fail
34957660
|
10 |
18.2 |
2022 |
|
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
|
Eur J Heart Fail
36325584
|
4 |
18.2 |
2022 |
|
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
35488811
|
6 |
18.2 |
2022 |
|
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
|
Eur J Heart Fail
35711093
|
0 |
18.2 |
2022 |
|
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
36073112
|
6 |
18.2 |
2022 |
|
Distinct pathophysiological pathways in women and men with heart failure.
|
Eur J Heart Fail
35596674
|
4 |
18.2 |
2022 |
|
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines.
|
Eur J Heart Fail
35579428
|
2 |
18.2 |
2022 |
|
Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
|
Eur J Heart Fail
35334136
|
3 |
18.2 |
2022 |
|
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.
|
Eur J Heart Fail
35083827
|
213 |
18.2 |
2022 |
|
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
|
Eur J Heart Fail
35239204
|
8 |
18.2 |
2022 |
|
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
|
Eur J Heart Fail
35279929
|
3 |
18.2 |
2022 |
|
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.
|
Eur J Heart Fail
36194680
|
3 |
18.2 |
2022 |
|
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial.
|
Eur J Heart Fail
36087309
|
1 |
18.2 |
2022 |
|
Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.
|
Eur J Heart Fail
35570197
|
3 |
18.2 |
2022 |
|
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.
|
Eur J Heart Fail
35604680
|
1 |
18.2 |
2022 |
|
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
|
Eur J Heart Fail
35748048
|
1 |
18.2 |
2022 |
|
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock.
|
Eur J Heart Fail
35729851
|
4 |
18.2 |
2022 |
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
|
Diabetes Care
35061867
|
6 |
16.2 |
2022 |
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
|
Diabetes Care
35972218
|
20 |
16.2 |
2022 |
|
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
|
JAMA Netw Open
36287567
|
3 |
13.8 |
2022 |
|
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome.
|
JACC Heart Fail
35654525
|
5 |
13 |
2022 |
|
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel.
|
JACC Heart Fail
36456063
|
3 |
13 |
2022 |
|
Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.
|
JACC Heart Fail
35361446
|
5 |
13 |
2022 |
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
JACC Heart Fail
36328655
|
8 |
13 |
2022 |
|
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
|
JACC Heart Fail
35670067
|
3 |
13 |
2022 |
|
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
|
JACC Heart Fail
35780032
|
5 |
13 |
2022 |
|
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure.
|
JACC Heart Fail
36049813
|
5 |
13 |
2022 |
|
The association between iron deficiency and outcomes: a secondary analysis of the intravenous iron therapy to treat iron deficiency anaemia in patients undergoing major abdominal surgery (PREVENTT) trial.
|
Anaesthesia
36477695
|
0 |
10.7 |
2022 |
|
Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure.
|
Clin J Am Soc Nephrol
35131929
|
2 |
10.624 |
2022 |
|
The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model.
|
J Cachexia Sarcopenia Muscle
36346141
|
3 |
8.9 |
2022 |
|
Clinical implications of low estimated protein intake in patients with heart failure.
|
J Cachexia Sarcopenia Muscle
35426256
|
5 |
8.9 |
2022 |
|
The erythropoietin-derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia.
|
J Cachexia Sarcopenia Muscle
35586884
|
0 |
8.9 |
2022 |
|
Identification and management of cancer cachexia in patients: Assessment of healthcare providers' knowledge and practice gaps.
|
J Cachexia Sarcopenia Muscle
36218155
|
6 |
8.9 |
2022 |
|
Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients.
|
Am J Transplant
35971851
|
4 |
8.8 |
2022 |
|
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
|
Hypertension
36252131
|
4 |
8.3 |
2022 |
|
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
|
Nephrol Dial Transplant
35451488
|
4 |
6.1 |
2022 |
|
Role of Cardiac Contractility Modulation in Heart Failure With a Higher Ejection Fraction.
|
J Card Fail
36122819
|
1 |
6 |
2022 |
|
Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency.
|
J Card Fail
36332897
|
1 |
6 |
2022 |
|
An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.
|
Kidney Int Rep
35967105
|
1 |
6 |
2022 |
|
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR).
|
Diabetes Obes Metab
36331803
|
2 |
5.8 |
2022 |
|
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
|
Diabetes Obes Metab
34908223
|
5 |
5.8 |
2022 |
|
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
|
Diabetes Obes Metab
36193847
|
3 |
5.8 |
2022 |
|
Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials.
|
J Am Heart Assoc
35876414
|
1 |
5.4 |
2022 |
|
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
|
J Am Heart Assoc
36565199
|
1 |
5.4 |
2022 |
|
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
|
Diabetes Res Clin Pract
35314257
|
2 |
5.1 |
2022 |
|
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.
|
Clin Res Cardiol
35294624
|
1 |
5 |
2022 |
|
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
|
J Hypertens
36583355
|
6 |
4.9 |
2022 |
|
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
|
Eur Heart J Cardiovasc Pharmacother
36251465
|
4 |
4.841 |
2022 |
|
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
|
Am Heart J
35595091
|
16 |
4.8 |
2022 |
|
Surrogate markers of gut dysfunction are related to heart failure severity and outcome-from the BIOSTAT-CHF consortium.
|
Am Heart J
35278373
|
4 |
4.8 |
2022 |
|
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.
|
Sci Rep
35595781
|
8 |
4.6 |
2022 |
|
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
|
Clin Kidney J
36864892
|
6 |
4.6 |
2022 |
|
Iron Deficiency and Reduced Muscle Strength in Patients with Acute and Chronic Ischemic Stroke.
|
J Clin Med
35160047
|
2 |
3.9 |
2022 |
|
Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence.
|
ESC Heart Fail
36088651
|
6 |
3.8 |
2022 |
|
Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.
|
ESC Heart Fail
36111511
|
5 |
3.8 |
2022 |
|
Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction.
|
ESC Heart Fail
35388650
|
2 |
3.8 |
2022 |
|
Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.
|
ESC Heart Fail
35029056
|
1 |
3.8 |
2022 |
|
Heart failure with normal LVEF in BIOSTAT-CHF.
|
Int J Cardiol
35649488
|
0 |
3.5 |
2022 |
|
Handgrip strength to screen early-onset sarcopenia in heart failure.
|
Clin Nutr ESPEN
35871922
|
1 |
3.058 |
2022 |
|
Glucose-Induced Hemodynamic and Metabolic Response of Skeletal Muscle in Heart Failure Patients with Reduced vs. Preserved Ejection Fraction-A Pilot Study.
|
J Cardiovasc Dev Dis
36547453
|
0 |
2.4 |
2022 |
|
Cardiac Cachexia Revisited: The Role of Wasting in Heart Failure.
|
Cardiol Clin
35465894
|
1 |
2.4 |
2022 |
|
Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol.
|
Clin Exp Emerg Med
35843615
|
1 |
0.01 |
2022 |
|
Exercise for Frail, Elderly Patients with Acute Heart Failure - A Strong Step Forward.
|
N Engl J Med
33999546
|
0 |
176.079 |
2021 |
|
Empagliflozin and Major Renal Outcomes in Heart Failure.
|
N Engl J Med
34449179
|
24 |
176.079 |
2021 |
|
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
|
N Engl J Med
34449181
|
215 |
176.079 |
2021 |
|
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
|
N Engl J Med
34449189
|
735 |
176.079 |
2021 |
|
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
|
Lancet Diabetes Endocrinol
34861154
|
7 |
44.5 |
2021 |
|
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
|
Circulation
34459213
|
65 |
39.918 |
2021 |
|
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
|
Circulation
34397263
|
2 |
39.918 |
2021 |
|
Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes".
|
Circulation
34516303
|
0 |
39.918 |
2021 |
|
Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials.
|
Circulation
34459212
|
12 |
39.918 |
2021 |
|
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
|
Eur Heart J
34618015
|
0 |
39.3 |
2021 |
|
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
|
Circulation
34779658
|
41 |
37.8 |
2021 |
|
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
|
Circulation
34775784
|
28 |
37.8 |
2021 |
|
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
|
Eur Heart J
33459776
|
25 |
35.855 |
2021 |
|
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
|
Eur Heart J
34184057
|
5 |
35.855 |
2021 |
|
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
|
Eur Heart J
33351892
|
40 |
35.855 |
2021 |
|
Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
|
Eur Heart J
34718518
|
1 |
35.855 |
2021 |
|
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
|
Eur Heart J
33420498
|
39 |
35.855 |
2021 |
|
Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
|
Eur Heart J
34875053
|
6 |
35.855 |
2021 |
|
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
|
Eur Heart J
34423361
|
7 |
35.855 |
2021 |
|
Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail.
|
Eur Heart J
33611381
|
1 |
35.855 |
2021 |
|
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
|
Eur Heart J
34447992
|
2045 |
35.855 |
2021 |
|
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
|
Eur Heart J
34080008
|
29 |
35.855 |
2021 |
|
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.
|
Eur Heart J
33734354
|
19 |
35.855 |
2021 |
|
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
|
J Am Coll Cardiol
34556320
|
10 |
27.203 |
2021 |
|
Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review.
|
J Am Coll Cardiol
34446165
|
9 |
27.203 |
2021 |
|
Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review.
|
J Am Coll Cardiol
33985688
|
7 |
27.203 |
2021 |
|
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
|
J Am Coll Cardiol
33736819
|
30 |
27.203 |
2021 |
|
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
|
J Am Coll Cardiol
33736821
|
32 |
27.203 |
2021 |
|
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
J Am Coll Cardiol
34015478
|
28 |
27.203 |
2021 |
|
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
|
J Am Coll Cardiol
34556318
|
18 |
27.203 |
2021 |
|
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
|
Eur J Heart Fail
34800079
|
10 |
18.2 |
2021 |
|
Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study.
|
Eur J Heart Fail
34816550
|
4 |
18.2 |
2021 |
|
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
|
Eur J Heart Fail
33651430
|
24 |
17.349 |
2021 |
|
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
|
Eur J Heart Fail
33742751
|
3 |
17.349 |
2021 |
|
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis.
|
Eur J Heart Fail
34628706
|
4 |
17.349 |
2021 |
|
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
|
Eur J Heart Fail
34010472
|
40 |
17.349 |
2021 |
|
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map.
|
Eur J Heart Fail
34173307
|
9 |
17.349 |
2021 |
|
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
|
Eur J Heart Fail
33340221
|
6 |
17.349 |
2021 |
|
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
|
Eur J Heart Fail
34459076
|
14 |
17.349 |
2021 |
|
One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
|
Eur J Heart Fail
33555114
|
10 |
17.349 |
2021 |
|
Advanced cancer is also a heart failure syndrome: a hypothesis.
|
Eur J Heart Fail
33247608
|
10 |
17.349 |
2021 |
|
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
|
Eur J Heart Fail
33728762
|
9 |
17.349 |
2021 |
|
Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
|
Eur J Heart Fail
33932255
|
10 |
17.349 |
2021 |
|
Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
|
Eur J Heart Fail
34173305
|
5 |
17.349 |
2021 |
|
COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
34612556
|
18 |
17.349 |
2021 |
|
Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study).
|
Eur J Heart Fail
33759308
|
1 |
17.349 |
2021 |
|
Can we trust a smartwatch ECG? Potential and limitations.
|
Eur J Heart Fail
33880842
|
2 |
17.349 |
2021 |
|
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
33932268
|
48 |
17.349 |
2021 |
|
Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
|
Eur J Heart Fail
33222388
|
10 |
17.349 |
2021 |
|
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.
|
Eur J Heart Fail
33605000
|
211 |
17.349 |
2021 |
|
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.
|
Eur J Heart Fail
34409711
|
5 |
17.349 |
2021 |
|
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
|
Eur J Heart Fail
34476878
|
10 |
17.349 |
2021 |
|
Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
|
Eur J Heart Fail
33998113
|
3 |
17.349 |
2021 |
|
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF.
|
Eur J Heart Fail
34164895
|
6 |
17.349 |
2021 |
|
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.
|
Eur J Heart Fail
34053177
|
7 |
17.349 |
2021 |
|
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
|
J Am Soc Nephrol
34732509
|
35 |
13.6 |
2021 |
|
Differences in biomarkers and molecular pathways according to age for patients with HFrEF.
|
Cardiovasc Res
33002110
|
5 |
13.081 |
2021 |
|
Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure.
|
JACC Heart Fail
34969496
|
4 |
13 |
2021 |
|
Impact of Geographic Region on the COMMANDER-HF Trial.
|
JACC Heart Fail
33549557
|
1 |
12.544 |
2021 |
|
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy.
|
JACC Heart Fail
34119470
|
4 |
12.544 |
2021 |
|
Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement.
|
JACC Heart Fail
33992567
|
2 |
12.544 |
2021 |
|
Prognostic impact of muscle and fat mass in patients with heart failure.
|
J Cachexia Sarcopenia Muscle
33939328
|
17 |
12.063 |
2021 |
|
Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?
|
J Cachexia Sarcopenia Muscle
34676694
|
7 |
12.063 |
2021 |
|
Advanced cancer is also a heart failure syndrome: a hypothesis.
|
J Cachexia Sarcopenia Muscle
33734609
|
7 |
12.063 |
2021 |
|
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021.
|
J Cachexia Sarcopenia Muscle
34904399
|
176 |
12.063 |
2021 |
|
The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure.
|
J Cachexia Sarcopenia Muscle
33742549
|
8 |
12.063 |
2021 |
|
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
|
Cardiovasc Res
34264317
|
5 |
10.8 |
2021 |
|
High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis.
|
Cardiovasc Res
34875022
|
2 |
10.8 |
2021 |
|
Pathophysiological pathways in patients with heart failure and atrial fibrillation.
|
Cardiovasc Res
34687289
|
2 |
10.8 |
2021 |
|
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
|
Cardiovasc Res
34390570
|
8 |
10.8 |
2021 |
|
Trends in 30- and 90-Day Readmission Rates for Heart Failure.
|
Circ Heart Fail
33866827
|
41 |
10.447 |
2021 |
|
Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry.
|
Eur J Intern Med
33896684
|
10 |
7.749 |
2021 |
|
Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact.
|
Clin Nutr
33483182
|
2 |
7.643 |
2021 |
|
Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review.
|
Nutrients
33477388
|
13 |
6.706 |
2021 |
|
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.
|
J Card Fail
33663906
|
114 |
6.592 |
2021 |
|
Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy.
|
J Card Fail
34022400
|
9 |
6.592 |
2021 |
|
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
|
J Card Fail
34364665
|
8 |
6.592 |
2021 |
|
Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care.
|
Cancers (Basel)
34065780
|
4 |
6.575 |
2021 |
|
Iron Deficiency in CKD Without Concomitant Anemia.
|
Kidney Int Rep
34805628
|
3 |
6.234 |
2021 |
|
Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
|
Clin Res Cardiol
33141252
|
0 |
6.138 |
2021 |
|
Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE.
|
Clin Res Cardiol
33686472
|
3 |
6.138 |
2021 |
|
Impaired High-Density Lipoprotein Function in Patients With Heart Failure.
|
J Am Heart Assoc
33870728
|
2 |
6.106 |
2021 |
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
Nephrol Dial Transplant
34850173
|
9 |
6.1 |
2021 |
|
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
|
Kidney Int Rep
35005312
|
23 |
6 |
2021 |
|
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
|
Diabetes Obes Metab
34580995
|
18 |
5.8 |
2021 |
|
Telomere length is independently associated with all-cause mortality in chronic heart failure.
|
Heart
33789973
|
2 |
5.7 |
2021 |
|
International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines.
|
J Nutr Health Aging
34409961
|
151 |
5.285 |
2021 |
|
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial.
|
Clin Res Cardiol
34128083
|
3 |
5 |
2021 |
|
Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring.
|
ESC Heart Fail
34738340
|
3 |
3.8 |
2021 |
|
Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial.
|
ESC Heart Fail
34545701
|
5 |
3.612 |
2021 |
|
Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment.
|
ESC Heart Fail
33955187
|
6 |
3.612 |
2021 |
|
HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community.
|
ESC Heart Fail
34519177
|
4 |
3.612 |
2021 |
|
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry.
|
ESC Heart Fail
33569926
|
9 |
3.612 |
2021 |
|
'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor.
|
ESC Heart Fail
34655282
|
18 |
3.612 |
2021 |
|
HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge.
|
ESC Heart Fail
34585525
|
4 |
3.612 |
2021 |
|
Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction.
|
ESC Heart Fail
33998162
|
16 |
3.612 |
2021 |
|
Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature.
|
ESC Heart Fail
34664409
|
3 |
3.612 |
2021 |
|
Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies.
|
ESC Heart Fail
34002946
|
2 |
3.612 |
2021 |
|
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.
|
ESC Heart Fail
34623032
|
12 |
3.612 |
2021 |
|
Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis.
|
ESC Heart Fail
33784028
|
1 |
3.612 |
2021 |
|
Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department.
|
ESC Heart Fail
34523254
|
4 |
3.612 |
2021 |
|
Safety and efficacy of iron supplementation after myocardial infarction in mice with moderate blood loss anaemia.
|
ESC Heart Fail
34636175
|
2 |
3.612 |
2021 |
|
Creating an impact, not an impression: ESC Heart Failure in its seventh year.
|
ESC Heart Fail
34622581
|
0 |
3.612 |
2021 |
|
The sarcopenia and physical frailty in older people: multi-component treatment strategies (SPRINTT) project: description and feasibility of a nutrition intervention in community-dwelling older Europeans.
|
Eur Geriatr Med
33583000
|
10 |
3.269 |
2021 |
|
Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.
|
Kidney360
35372992
|
1 |
2.3 |
2021 |
|
[Diagnosing atrial fibrillation using a smartwatch].
|
Nervenarzt
33929553
|
0 |
1.1 |
2021 |
|
Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom.
|
Int J Heart Fail
36262556
|
1 |
0 |
2021 |
|
Roxadustat for Anemia in Patients with Chronic Kidney Disease.
|
N Engl J Med
32609998
|
4 |
91.245 |
2020 |
|
Liraglutide for Adolescents with Obesity.
|
N Engl J Med
32937055
|
0 |
91.245 |
2020 |
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
N Engl J Med
33264825
|
436 |
91.245 |
2020 |
|
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
|
N Engl J Med
32865377
|
1032 |
91.245 |
2020 |
|
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
|
Circulation
33095032
|
65 |
39.918 |
2020 |
|
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
Circulation
33198491
|
75 |
39.918 |
2020 |
|
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
|
Circulation
33175585
|
87 |
39.918 |
2020 |
|
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
|
Circulation
33081531
|
73 |
39.918 |
2020 |
|
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
|
Lancet Diabetes Endocrinol
33217335
|
14 |
32.069 |
2020 |
|
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial.
|
Eur Heart J
32402060
|
25 |
29.983 |
2020 |
|
Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
|
Eur Heart J
32935133
|
8 |
29.983 |
2020 |
|
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
|
Eur Heart J
32498081
|
36 |
29.983 |
2020 |
|
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
|
Eur Heart J
32388565
|
239 |
29.983 |
2020 |
|
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
|
Circulation
32955939
|
20 |
29.69 |
2020 |
|
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review.
|
J Am Coll Cardiol
32498812
|
32 |
24.094 |
2020 |
|
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.
|
J Am Coll Cardiol
33183511
|
22 |
24.094 |
2020 |
|
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
|
J Am Coll Cardiol
32192799
|
14 |
24.094 |
2020 |
|
Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF.
|
Eur J Heart Fail
32216000
|
5 |
17.349 |
2020 |
|
Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
|
Eur J Heart Fail
32959502
|
4 |
17.349 |
2020 |
|
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality.
|
Eur J Heart Fail
33111457
|
21 |
17.349 |
2020 |
|
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure.
|
Eur J Heart Fail
33111389
|
14 |
17.349 |
2020 |
|
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
|
Eur J Heart Fail
33063412
|
13 |
17.349 |
2020 |
|
Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
|
Eur J Heart Fail
33068051
|
21 |
15.534 |
2020 |
|
Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
32618086
|
36 |
15.534 |
2020 |
|
Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
32463543
|
54 |
15.534 |
2020 |
|
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.
|
Eur J Heart Fail
33017862
|
7 |
15.534 |
2020 |
|
Ten lessons from the EMPEROR-Reduced trial.
|
Eur J Heart Fail
32949160
|
1 |
15.534 |
2020 |
|
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
|
Eur J Heart Fail
33251670
|
34 |
15.534 |
2020 |
|
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
|
Eur J Heart Fail
32239794
|
26 |
15.534 |
2020 |
|
Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
32469155
|
76 |
15.534 |
2020 |
|
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
|
Eur J Heart Fail
32243695
|
12 |
15.534 |
2020 |
|
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
|
Eur J Heart Fail
32243669
|
26 |
15.534 |
2020 |
|
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
|
Eur J Heart Fail
32133741
|
76 |
15.534 |
2020 |
|
Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF.
|
Eur J Heart Fail
32666670
|
2 |
15.534 |
2020 |
|
Genetic risk and atrial fibrillation in patients with heart failure.
|
Eur J Heart Fail
31919934
|
6 |
15.534 |
2020 |
|
Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
|
Eur J Heart Fail
32583922
|
6 |
15.534 |
2020 |
|
Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure.
|
Eur J Heart Fail
32232914
|
2 |
15.534 |
2020 |
|
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
|
Eur J Heart Fail
32237110
|
11 |
15.534 |
2020 |
|
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
|
Eur J Heart Fail
33094495
|
37 |
15.534 |
2020 |
|
Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
|
Eur J Heart Fail
32463544
|
0 |
15.534 |
2020 |
|
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
|
Eur J Heart Fail
33251659
|
8 |
15.534 |
2020 |
|
Trends in prevalence of comorbidities in heart failure clinical trials.
|
Eur J Heart Fail
32293090
|
23 |
15.534 |
2020 |
|
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
|
Eur J Heart Fail
32078214
|
14 |
15.534 |
2020 |
|
Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF).
|
Eur J Heart Fail
32592227
|
47 |
15.534 |
2020 |
|
COVID-19: a major cause of cachexia and sarcopenia?
|
J Cachexia Sarcopenia Muscle
32519505
|
87 |
12.91 |
2020 |
|
Muscle wasting as an independent predictor of survival in patients with chronic heart failure.
|
J Cachexia Sarcopenia Muscle
32767518
|
40 |
12.91 |
2020 |
|
Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference.
|
J Cachexia Sarcopenia Muscle
32049447
|
12 |
12.91 |
2020 |
|
MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia.
|
J Cachexia Sarcopenia Muscle
32067370
|
9 |
12.91 |
2020 |
|
Nutrition in the spotlight in cachexia, sarcopenia and muscle: avoiding the wildfire.
|
J Cachexia Sarcopenia Muscle
33382196
|
19 |
12.063 |
2020 |
|
Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers.
|
J Cachexia Sarcopenia Muscle
33382211
|
54 |
12.063 |
2020 |
|
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
|
JACC Heart Fail
32171760
|
2 |
12.035 |
2020 |
|
Distinct Pathological Pathways in Patients With Heart Failure and Diabetes.
|
JACC Heart Fail
32035890
|
14 |
12.035 |
2020 |
|
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium.
|
JACC Heart Fail
33199251
|
8 |
12.035 |
2020 |
|
Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.
|
J Am Soc Nephrol
32253271
|
26 |
10.121 |
2020 |
|
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
|
Lancet
33197395
|
146 |
9.153 |
2020 |
|
Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial.
|
Lancet
32896294
|
53 |
9.153 |
2020 |
|
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
|
Lancet
32877652
|
294 |
9.153 |
2020 |
|
Tumour biomarkers: association with heart failure outcomes.
|
J Intern Med
32372544
|
19 |
8.989 |
2020 |
|
Cardiovascular implications of COVID-19 versus influenza infection: a review.
|
BMC Med
33334360
|
28 |
8.775 |
2020 |
|
Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results.
|
JAMA Netw Open
32756927
|
13 |
8.483 |
2020 |
|
Assessment of coronary artery disease during hospitalization for cancer treatment.
|
Clin Res Cardiol
32743679
|
6 |
6.138 |
2020 |
|
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
|
Nephrol Dial Transplant
33280027
|
24 |
6.1 |
2020 |
|
A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure.
|
Nutrients
32825781
|
11 |
5.717 |
2020 |
|
Preserved Skeletal Muscle Mitochondrial Function, Redox State, Inflammation and Mass in Obese Mice with Chronic Heart Failure.
|
Nutrients
33158222
|
4 |
5.717 |
2020 |
|
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.
|
J Card Fail
32068002
|
26 |
5.712 |
2020 |
|
Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study.
|
Clin Res Cardiol
31996990
|
1 |
5.46 |
2020 |
|
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
|
Clin Res Cardiol
32002631
|
7 |
5.46 |
2020 |
|
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
|
Clin Res Cardiol
32236720
|
27 |
5.46 |
2020 |
|
Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II.
|
Europace
32330937
|
4 |
5.214 |
2020 |
|
Decreased Appendicular Skeletal Muscle Mass is Associated with Poor Outcomes after ST-Segment Elevation Myocardial Infarction.
|
J Atheroscler Thromb
32132340
|
11 |
4.928 |
2020 |
|
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
|
J Hypertens
32618884
|
5 |
4.844 |
2020 |
|
The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial.
|
ESC Heart Fail
32700409
|
5 |
4.411 |
2020 |
|
Early rehabilitation after stroke: relationship between the heart rate variability and functional outcome.
|
ESC Heart Fail
33121218
|
6 |
4.411 |
2020 |
|
Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies.
|
ESC Heart Fail
32860353
|
2 |
4.411 |
2020 |
|
The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!
|
ESC Heart Fail
33320445
|
1 |
4.411 |
2020 |
|
Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.
|
ESC Heart Fail
32662949
|
7 |
4.411 |
2020 |
|
Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry.
|
ESC Heart Fail
32618139
|
12 |
4.411 |
2020 |
|
Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure.
|
ESC Heart Fail
32167681
|
5 |
4.411 |
2020 |
|
Heart failure and sleep-disordered breathing: susceptibility to reduced muscle strength and preclinical congestion (SICA-HF cohort).
|
ESC Heart Fail
32578399
|
5 |
4.411 |
2020 |
|
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
|
ESC Heart Fail
33586910
|
28 |
4.411 |
2020 |
|
Hypokalaemia and outcomes in older patients hospitalized for heart failure.
|
ESC Heart Fail
32319205
|
4 |
4.411 |
2020 |
|
Anaemia, iron deficiency and heart failure in 2020: facts and numbers.
|
ESC Heart Fail
32602663
|
26 |
4.411 |
2020 |
|
Acute effects of oral triglyceride load on dynamic changes in peripheral endothelial function in heart failure patients with reduced ejection fraction and healthy controls.
|
Nutr Metab Cardiovasc Dis
32682746
|
1 |
4.222 |
2020 |
|
Correction to: Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis.
|
Lipids Health Dis
32951597
|
0 |
3.876 |
2020 |
|
Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results.
|
ESC Heart Fail
33191637
|
3 |
3.612 |
2020 |
|
Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.
|
ESC Heart Fail
33254286
|
3 |
3.612 |
2020 |
|
Prognostic impact of 6 min walk test distance in patients with systolic heart failure: insights from the WARCEF trial.
|
ESC Heart Fail
33377631
|
2 |
3.612 |
2020 |
|
Cardiac Cachexia Revisited: The Role of Wasting in Heart Failure.
|
Heart Fail Clin
31735316
|
15 |
3.179 |
2020 |
|
Major Depression and Anxiety Among Patients Hospitalized With Heart Failure.
|
Am J Cardiol
33383015
|
0 |
3.133 |
2020 |
|
Effects of Serelaxin in Patients with Acute Heart Failure.
|
N Engl J Med
31433919
|
58 |
74.699 |
2019 |
|
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
|
N Engl J Med
31475794
|
551 |
74.699 |
2019 |
|
Redefining Heart Failure With a Reduced Ejection Fraction.
|
JAMA
31517955
|
24 |
45.54 |
2019 |
|
Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial.
|
Lancet Digit Health
33328035
|
10 |
24.519 |
2019 |
|
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
|
J Am Coll Cardiol
31726194
|
26 |
24.094 |
2019 |
|
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
|
Circulation
30586730
|
194 |
23.603 |
2019 |
|
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
|
Circulation
31841369
|
7 |
23.603 |
2019 |
|
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
|
Eur Heart J
31504452
|
320 |
22.673 |
2019 |
|
Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.
|
Eur Heart J
30226525
|
6 |
22.673 |
2019 |
|
Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.
|
Eur Heart J
31556953
|
30 |
22.673 |
2019 |
|
The evolving obesity paradigm story: from heart failure to atrial fibrillation.
|
Eur Heart J
31009055
|
0 |
22.673 |
2019 |
|
Mode-of-action of the PROPELLA concept in fulminant myocarditis.
|
Eur Heart J
30891599
|
21 |
22.673 |
2019 |
|
Treatments targeting inotropy.
|
Eur Heart J
30295807
|
49 |
22.673 |
2019 |
|
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
|
Eur Heart J
31461239
|
23 |
22.673 |
2019 |
|
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.
|
J Am Coll Cardiol
31806133
|
15 |
20.589 |
2019 |
|
Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
31815347
|
13 |
15.534 |
2019 |
|
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
|
Eur J Heart Fail
31820559
|
29 |
15.534 |
2019 |
|
Selenium and outcome in heart failure.
|
Eur J Heart Fail
31808274
|
42 |
15.534 |
2019 |
|
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
|
Eur J Heart Fail
31692186
|
12 |
15.534 |
2019 |
|
Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry.
|
Eur J Heart Fail
31863522
|
24 |
15.534 |
2019 |
|
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
|
Eur J Heart Fail
31713324
|
21 |
15.534 |
2019 |
|
Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study.
|
Eur J Heart Fail
31793144
|
5 |
15.534 |
2019 |
|
The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
|
Eur J Heart Fail
31797504
|
14 |
15.534 |
2019 |
|
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
|
Eur J Heart Fail
31816162
|
38 |
15.534 |
2019 |
|
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
|
JAMA Cardiol
31017637
|
14 |
12.794 |
2019 |
|
Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.
|
JAMA Cardiol
31188392
|
18 |
12.794 |
2019 |
|
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
31129923
|
191 |
11.627 |
2019 |
|
Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
30989768
|
94 |
11.627 |
2019 |
|
Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.
|
Eur J Heart Fail
30892806
|
15 |
11.627 |
2019 |
|
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
|
Eur J Heart Fail
31584231
|
47 |
11.627 |
2019 |
|
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
|
Eur J Heart Fail
31523904
|
77 |
11.627 |
2019 |
|
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
|
Eur J Heart Fail
31132222
|
15 |
11.627 |
2019 |
|
Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
|
Eur J Heart Fail
30933403
|
29 |
11.627 |
2019 |
|
Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial.
|
Eur J Heart Fail
31129917
|
17 |
11.627 |
2019 |
|
Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis.
|
Eur J Heart Fail
31353762
|
11 |
11.627 |
2019 |
|
Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure.
|
Eur J Heart Fail
31646718
|
66 |
11.627 |
2019 |
|
Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.
|
Eur J Heart Fail
31243866
|
81 |
11.627 |
2019 |
|
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
|
Eur J Heart Fail
31218819
|
16 |
11.627 |
2019 |
|
Novel potassium binders as enabling therapy in heart failure.
|
Eur J Heart Fail
30993820
|
2 |
11.627 |
2019 |
|
Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM-HF2 trial.
|
Eur J Heart Fail
31129929
|
8 |
11.627 |
2019 |
|
Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.
|
Eur J Heart Fail
31209992
|
6 |
11.627 |
2019 |
|
Less invasive ventricular reconstruction for ischaemic heart failure.
|
Eur J Heart Fail
31797492
|
13 |
11.627 |
2019 |
|
ESC Heart Failure receives its first impact factor.
|
Eur J Heart Fail
31883221
|
0 |
11.627 |
2019 |
|
Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.
|
Eur J Heart Fail
30600578
|
9 |
11.627 |
2019 |
|
Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
|
Eur J Heart Fail
30843353
|
34 |
11.627 |
2019 |
|
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
|
Eur J Heart Fail
31883356
|
20 |
11.627 |
2019 |
|
The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.
|
Eur J Heart Fail
31087601
|
79 |
11.627 |
2019 |
|
Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.
|
Eur J Heart Fail
30652394
|
17 |
11.627 |
2019 |
|
The Journal of Cachexia, Sarcopenia and Muscle in 2019.
|
J Cachexia Sarcopenia Muscle
31454183
|
1 |
9.802 |
2019 |
|
Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference.
|
J Cachexia Sarcopenia Muscle
30920774
|
13 |
9.802 |
2019 |
|
Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.
|
J Cachexia Sarcopenia Muscle
30920776
|
59 |
9.802 |
2019 |
|
Body weight changes and incidence of cachexia after stroke.
|
J Cachexia Sarcopenia Muscle
30680953
|
17 |
9.802 |
2019 |
|
The Journal of Cachexia, Sarcopenia and Muscle stays the front-runner in geriatrics and gerontology.
|
J Cachexia Sarcopenia Muscle
31821753
|
1 |
9.802 |
2019 |
|
Sarcopenia: A Time for Action. An SCWD Position Paper.
|
J Cachexia Sarcopenia Muscle
31523937
|
174 |
9.802 |
2019 |
|
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019.
|
J Cachexia Sarcopenia Muscle
31661195
|
306 |
9.802 |
2019 |
|
A tissue-specific screen of ceramide expression in aged mice identifies ceramide synthase-1 and ceramide synthase-5 as potential regulators of fiber size and strength in skeletal muscle.
|
Aging Cell
31692231
|
9 |
9.304 |
2019 |
|
Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF.
|
JACC Heart Fail
31779926
|
10 |
9.14 |
2019 |
|
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
|
Kidney Int
31053387
|
96 |
8.945 |
2019 |
|
Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
|
Lancet
31447116
|
50 |
8.043 |
2019 |
|
Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.
|
Circ Heart Fail
31091993
|
13 |
6.033 |
2019 |
|
ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine.
|
Eur J Prev Cardiol
30917695
|
84 |
5.864 |
2019 |
|
The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
|
Clin Res Cardiol
31263996
|
12 |
5.46 |
2019 |
|
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.
|
Clin Res Cardiol
30610382
|
5 |
5.268 |
2019 |
|
Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF.
|
Eur J Intern Med
31708361
|
5 |
4.487 |
2019 |
|
Remote monitoring of implantable cardioverter-defibrillators and resynchronization devices to improve patient outcomes: dead end or way ahead?
|
Europace
30903152
|
8 |
4.045 |
2019 |
|
The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction.
|
EuroIntervention
31130524
|
15 |
3.993 |
2019 |
|
Heart failure prevalence in the general population: SOBOTA-HF study rationale and design.
|
ESC Heart Fail
31347289
|
3 |
3.902 |
2019 |
|
Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
|
ESC Heart Fail
30816013
|
5 |
3.902 |
2019 |
|
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.
|
ESC Heart Fail
31148411
|
10 |
3.902 |
2019 |
|
Open access efforts begin to bloom: ESC Heart Failure gets full attention and first impact factor.
|
ESC Heart Fail
31657535
|
0 |
3.902 |
2019 |
|
Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction.
|
Eur J Clin Invest
30801690
|
1 |
3.481 |
2019 |
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
Am J Nephrol
31655812
|
36 |
3.411 |
2019 |
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
Am J Nephrol
31665733
|
48 |
3.411 |
2019 |
|
Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis.
|
Lipids Health Dis
31672151
|
12 |
2.906 |
2019 |
|
Novel biomarkers in heart failure and cardio-oncology.
|
Kardiol Pol
30912110
|
1 |
1.874 |
2019 |
|
New treatments for hyperkalaemia: clinical use in cardiology.
|
Eur Heart J Suppl
30837804
|
2 |
1.655 |
2019 |
|
Sympatho-Vagal Imbalance is Associated with Sarcopenia in Male Patients with Heart Failure.
|
Arq Bras Cardiol
30970141
|
8 |
1.45 |
2019 |
|
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
|
N Engl J Med
30365356
|
139 |
74.699 |
2018 |
|
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
|
N Engl J Med
30406980
|
2 |
70.67 |
2018 |
|
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
|
N Engl J Med
30146935
|
86 |
70.67 |
2018 |
|
Enzalutamide in Castration-Resistant Prostate Cancer.
|
N Engl J Med
30284800
|
0 |
70.67 |
2018 |
|
Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
|
Eur Heart J
30137304
|
17 |
23.239 |
2018 |
|
Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.
|
Eur Heart J
29370377
|
77 |
23.239 |
2018 |
|
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
|
Eur Heart J
30325423
|
77 |
23.239 |
2018 |
|
Novel endotypes in heart failure: effects on guideline-directed medical therapy.
|
Eur Heart J
30551207
|
20 |
23.239 |
2018 |
|
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.
|
J Am Coll Cardiol
29389354
|
18 |
18.639 |
2018 |
|
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.
|
J Am Coll Cardiol
30165978
|
98 |
18.639 |
2018 |
|
Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention.
|
Eur J Heart Fail
30230666
|
27 |
13.965 |
2018 |
|
Corrigendum to 'Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2018;20:3-15].
|
Eur J Heart Fail
30303623
|
2 |
13.965 |
2018 |
|
Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities.
|
Eur J Heart Fail
29943887
|
19 |
13.965 |
2018 |
|
Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
Eur J Heart Fail
30160804
|
65 |
13.965 |
2018 |
|
Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
|
Eur J Heart Fail
29578280
|
59 |
13.965 |
2018 |
|
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
29520964
|
169 |
13.965 |
2018 |
|
PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.
|
Eur J Heart Fail
29846031
|
6 |
13.965 |
2018 |
|
Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
|
Eur J Heart Fail
29327797
|
21 |
13.965 |
2018 |
|
Waist-to-hip ratio and mortality in heart failure.
|
Eur J Heart Fail
29963737
|
38 |
13.965 |
2018 |
|
CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?
|
Eur J Heart Fail
29457358
|
37 |
13.965 |
2018 |
|
The new Heart Failure Association journal - ESC Heart Failure.
|
Eur J Heart Fail
30561163
|
0 |
13.965 |
2018 |
|
The Obesity Paradigm and Lifetime Risk of Cardiovascular Disease.
|
JAMA Cardiol
29998316
|
2 |
11.866 |
2018 |
|
Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF.
|
Eur J Heart Fail
30370976
|
33 |
11.627 |
2018 |
|
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
|
Eur J Heart Fail
30338883
|
20 |
11.627 |
2018 |
|
Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival.
|
Eur J Heart Fail
30191647
|
1 |
11.627 |
2018 |
|
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.
|
Eur J Heart Fail
30537163
|
16 |
11.627 |
2018 |
|
Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018.
|
J Cachexia Sarcopenia Muscle
30311438
|
4 |
10.754 |
2018 |
|
From meta-analysis to Cochrane reviews.
|
J Cachexia Sarcopenia Muscle
29873945
|
1 |
10.754 |
2018 |
|
More variety with the Journal of Cachexia, Sarcopenia and Muscle: JCSM Clinical Reports and JCSM Rapid Communications have both gone live.
|
J Cachexia Sarcopenia Muscle
29608044
|
2 |
10.754 |
2018 |
|
Iron deficiency as energetic insult to skeletal muscle in chronic diseases.
|
J Cachexia Sarcopenia Muscle
30178922
|
25 |
10.754 |
2018 |
|
Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018.
|
J Cachexia Sarcopenia Muscle
30450844
|
1 |
10.754 |
2018 |
|
Iron Deficiency in Heart Failure: An Overview.
|
JACC Heart Fail
30553903
|
94 |
9.14 |
2018 |
|
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial.
|
Lancet
30153985
|
213 |
9.098 |
2018 |
|
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
|
Circ Heart Fail
29980595
|
43 |
6.526 |
2018 |
|
Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life.
|
Clin Res Cardiol
30051186
|
33 |
5.268 |
2018 |
|
Expert opinion paper on atrial fibrillation detection after ischemic stroke.
|
Clin Res Cardiol
29704214
|
26 |
4.907 |
2018 |
|
Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF).
|
Clin Res Cardiol
29777373
|
24 |
4.907 |
2018 |
|
Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome.
|
Biomolecules
30037035
|
15 |
4.694 |
2018 |
|
Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy.
|
ESC Heart Fail
30367561
|
7 |
3.902 |
2018 |
|
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease.
|
J Card Fail
30423457
|
9 |
3.623 |
2018 |
|
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
|
Eur Heart J Cardiovasc Pharmacother
29726985
|
35 |
3.512 |
2018 |
|
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.
|
Int J Cardiol
29306478
|
28 |
3.471 |
2018 |
|
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.
|
Int J Cardiol
30482453
|
55 |
3.471 |
2018 |
|
Mobile health applications in cardiovascular research.
|
Int J Cardiol
29921516
|
6 |
3.471 |
2018 |
|
Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle.
|
ESC Heart Fail
30024112
|
14 |
3.407 |
2018 |
|
Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment.
|
ESC Heart Fail
30015405
|
16 |
3.407 |
2018 |
|
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
|
ESC Heart Fail
29932311
|
15 |
3.407 |
2018 |
|
Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference?
|
ESC Heart Fail
29667356
|
3 |
3.407 |
2018 |
|
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
|
Am J Nephrol
30304714
|
16 |
2.961 |
2018 |
|
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.
|
Clin Proteomics
30410428
|
3 |
2.892 |
2018 |
|
Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).
|
Am J Cardiol
30037426
|
1 |
2.843 |
2018 |
|
International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.
|
J Nutr Health Aging
30498820
|
246 |
2.66 |
2018 |
|
Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.
|
Arch Med Sci
30002709
|
22 |
2.38 |
2018 |
|
Therapeutic considerations of sarcopenia in heart failure patients.
|
Expert Rev Cardiovasc Ther
29308681
|
4 |
1.678 |
2018 |
|
The importance of registries in today's heart failure therapies.
|
Kardiol Pol
29984809
|
0 |
1.674 |
2018 |
|
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
|
N Engl J Med
28845751
|
2778 |
79.258 |
2017 |
|
Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.
|
N Engl J Med
28517922
|
1 |
79.258 |
2017 |
|
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.
|
N Engl J Med
28402745
|
96 |
79.258 |
2017 |
|
Big Data in Cardiovascular Disease.
|
Eur Heart J
28863460
|
9 |
23.425 |
2017 |
|
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
|
Eur Heart J
28329163
|
104 |
23.425 |
2017 |
|
Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST).
|
Eur Heart J
29688304
|
52 |
23.425 |
2017 |
|
The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
|
Circulation
29038205
|
5 |
18.88 |
2017 |
|
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
|
Circulation
28701470
|
116 |
18.88 |
2017 |
|
Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction.
|
J Am Coll Cardiol
28982499
|
16 |
16.834 |
2017 |
|
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis.
|
J Am Coll Cardiol
29050560
|
13 |
16.834 |
2017 |
|
Role of microRNAs in wasting in heart failure.
|
Nat Rev Cardiol
28770867
|
4 |
15.162 |
2017 |
|
Muscle wasting and cachexia in heart failure: mechanisms and therapies.
|
Nat Rev Cardiol
28436486
|
101 |
15.162 |
2017 |
|
Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
28925073
|
50 |
13.965 |
2017 |
|
Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association.
|
Eur J Heart Fail
29280256
|
50 |
13.965 |
2017 |
|
Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.
|
Eur J Heart Fail
29251807
|
13 |
13.965 |
2017 |
|
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
|
Eur J Heart Fail
28436136
|
124 |
13.965 |
2017 |
|
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
|
Eur J Heart Fail
28980368
|
3 |
13.965 |
2017 |
|
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry.
|
Diabetes Care
28255009
|
38 |
13.397 |
2017 |
|
Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.
|
J Cachexia Sarcopenia Muscle
28244261
|
33 |
12.511 |
2017 |
|
Myopenia and precision (P4) medicine.
|
J Cachexia Sarcopenia Muscle
28944582
|
16 |
12.511 |
2017 |
|
Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017.
|
J Cachexia Sarcopenia Muscle
29098794
|
246 |
12.511 |
2017 |
|
Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.
|
J Cachexia Sarcopenia Muscle
29076661
|
6 |
12.511 |
2017 |
|
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
|
Eur J Heart Fail
28836359
|
59 |
10.683 |
2017 |
|
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure.
|
Eur J Heart Fail
28247565
|
83 |
10.683 |
2017 |
|
Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
|
Eur J Heart Fail
28560824
|
3 |
10.683 |
2017 |
|
Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
|
Eur J Heart Fail
28463464
|
79 |
10.683 |
2017 |
|
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
|
Eur J Heart Fail
28386917
|
224 |
10.683 |
2017 |
|
Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases.
|
Eur J Heart Fail
28271595
|
7 |
10.683 |
2017 |
|
New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.
|
Eur J Heart Fail
28345190
|
2 |
10.683 |
2017 |
|
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
|
Eur J Heart Fail
28580625
|
26 |
10.683 |
2017 |
|
Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: preliminary experience. A report from the SICA-HF study.
|
Eur J Heart Fail
28387033
|
10 |
10.683 |
2017 |
|
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.
|
Eur J Heart Fail
28463462
|
115 |
10.683 |
2017 |
|
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
|
JAMA Cardiol
28768320
|
114 |
10.133 |
2017 |
|
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
|
Lancet
28855077
|
468 |
9.482 |
2017 |
|
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
|
Lancet
29146124
|
278 |
9.098 |
2017 |
|
Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.
|
JACC Heart Fail
28774396
|
1 |
8.202 |
2017 |
|
Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure.
|
J Am Med Dir Assoc
28501416
|
3 |
5.325 |
2017 |
|
Coronary angiography in worsening heart failure: determinants, findings and prognostic implications.
|
Heart
28798192
|
6 |
5.082 |
2017 |
|
Sleep-Disordered Breathing in Acute Ischemic Stroke: A Mechanistic Link to Peripheral Endothelial Dysfunction.
|
J Am Heart Assoc
28893762
|
4 |
4.45 |
2017 |
|
Models of sarcopenia: Short review.
|
Int J Cardiol
28465116
|
19 |
4.034 |
2017 |
|
Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study.
|
Int J Cardiol
28343761
|
9 |
4.034 |
2017 |
|
Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study.
|
Int J Cardiol
28291625
|
7 |
4.034 |
2017 |
|
Treatment of systolic hypertension and low diastolic blood pressure in older adults: How low is too low?!
|
Int J Cardiol
28619324
|
1 |
4.034 |
2017 |
|
Animal models of cachexia and sarcopenia in chronic illness: Cardiac function, body composition changes and therapeutic results.
|
Int J Cardiol
28476513
|
17 |
4.034 |
2017 |
|
Myostatin signaling is up-regulated in female patients with advanced heart failure.
|
Int J Cardiol
28465115
|
13 |
4.034 |
2017 |
|
Corrigendum to "Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the cardiovascular health study" [Int. J. Cardiol. 235 (2017) 11-16].
|
Int J Cardiol
28487149
|
1 |
4.034 |
2017 |
|
Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016.
|
Int J Cardiol
28427849
|
26 |
4.034 |
2017 |
|
Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry.
|
J Card Fail
29029965
|
63 |
3.942 |
2017 |
|
Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
|
Handb Exp Pharmacol
28382468
|
6 |
3.798 |
2017 |
|
The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke.
|
Front Neurol
28484421
|
18 |
3.385 |
2017 |
|
Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure.
|
Cerebrovasc Dis
28419982
|
4 |
2.931 |
2017 |
|
Biomarkers for physical frailty and sarcopenia.
|
Aging Clin Exp Res
28155180
|
20 |
2.121 |
2017 |
|
[Iron Deficiency in Chronic Heart Failure: Diagnostic Algorithm and Present-Day Therapeutic Options].
|
Dtsch Med Wochenschr
28303555
|
3 |
0.523 |
2017 |
|
[Iron deficiency : Recognition and treatment].
|
Internist (Berl)
28540476
|
0 |
0.44 |
2017 |
|
Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
|
ESC Heart Fail
28869332
|
21 |
0 |
2017 |
|
Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
ESC Heart Fail
28960880
|
39 |
0 |
2017 |
|
Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.
|
ESC Heart Fail
28772051
|
9 |
0 |
2017 |
|
Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients.
|
Clin Kidney J
29225820
|
3 |
0 |
2017 |
|
Muscle wasting and sarcopenia in heart failure and beyond: update 2017.
|
ESC Heart Fail
29154428
|
73 |
0 |
2017 |
|
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
|
N Engl J Med
27532847
|
0 |
72.406 |
2016 |
|
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
|
N Engl J Med
27043774
|
82 |
72.406 |
2016 |
|
Weight Loss and Health Status after Bariatric Surgery in Adolescents.
|
N Engl J Med
27192679
|
2 |
72.406 |
2016 |
|
Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.
|
Eur Heart J
26865478
|
62 |
20.212 |
2016 |
|
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
|
Eur Heart J
27206819
|
4097 |
20.212 |
2016 |
|
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
|
Eur Heart J
27130705
|
95 |
20.212 |
2016 |
|
Hyperkalemia in Heart Failure.
|
J Am Coll Cardiol
27687200
|
36 |
19.896 |
2016 |
|
Diabetes and Heart Failure: Sugared Words Prove Bitter.
|
J Am Coll Cardiol
27659463
|
1 |
19.896 |
2016 |
|
Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.
|
Nat Rev Cardiol
28004807
|
284 |
15.162 |
2016 |
|
Heart failure and kidney dysfunction: epidemiology, mechanisms and management.
|
Nat Rev Nephrol
27573728
|
193 |
12.146 |
2016 |
|
In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry.
|
Eur J Heart Fail
27790816
|
50 |
10.683 |
2016 |
|
Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.
|
Eur J Heart Fail
27862700
|
15 |
10.683 |
2016 |
|
Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study.
|
Eur J Heart Fail
27976478
|
17 |
10.683 |
2016 |
|
Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials.
|
Eur J Heart Fail
27634736
|
14 |
10.683 |
2016 |
|
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).
|
J Cachexia Sarcopenia Muscle
27386169
|
61 |
9.697 |
2016 |
|
Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation.
|
J Cachexia Sarcopenia Muscle
27239419
|
30 |
9.697 |
2016 |
|
Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016.
|
J Cachexia Sarcopenia Muscle
27891294
|
101 |
9.697 |
2016 |
|
Welcome to the ICD-10 code for sarcopenia.
|
J Cachexia Sarcopenia Muscle
27891296
|
257 |
9.697 |
2016 |
|
Nutrition in cachexia: from bench to bedside.
|
J Cachexia Sarcopenia Muscle
27030816
|
17 |
9.697 |
2016 |
|
Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016.
|
J Cachexia Sarcopenia Muscle
27625918
|
3 |
9.697 |
2016 |
|
Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact.
|
J Cachexia Sarcopenia Muscle
27239422
|
12 |
9.697 |
2016 |
|
The times they are a-changin': the Cachexia Conference goes annual.
|
J Cachexia Sarcopenia Muscle
27066313
|
4 |
9.697 |
2016 |
|
Concerning the Role of Gender Difference in Obesity Paradox in Patients With Heart Failure.
|
JACC Heart Fail
26940631
|
1 |
8.493 |
2016 |
|
Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
|
Kidney Int
26759045
|
105 |
8.395 |
2016 |
|
Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials.
|
Eur J Heart Fail
26821594
|
99 |
6.968 |
2016 |
|
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
|
Eur J Heart Fail
27207191
|
2070 |
6.968 |
2016 |
|
Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
27198159
|
10 |
6.968 |
2016 |
|
The incremental prognostic and clinical value of multiple novel biomarkers in heart failure.
|
Eur J Heart Fail
27114189
|
24 |
6.968 |
2016 |
|
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
|
Eur J Heart Fail
27071916
|
25 |
6.968 |
2016 |
|
Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study.
|
Eur J Heart Fail
27910284
|
40 |
6.968 |
2016 |
|
ESC Heart Failure: a new journal aims to broaden heart failure views.
|
Eur J Heart Fail
27910285
|
0 |
6.968 |
2016 |
|
Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
|
Eur J Heart Fail
27095461
|
69 |
6.968 |
2016 |
|
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.
|
Eur J Heart Fail
27126231
|
59 |
6.968 |
2016 |
|
Systematic review and meta-analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review.
|
Eur J Heart Fail
27121474
|
17 |
6.968 |
2016 |
|
CHA DS -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm.
|
Eur J Heart Fail
27444219
|
9 |
6.968 |
2016 |
|
Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489].
|
Eur J Heart Fail
27324688
|
0 |
6.968 |
2016 |
|
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
|
Eur J Heart Fail
27324686
|
200 |
6.968 |
2016 |
|
Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum.
|
Eur J Heart Fail
27220672
|
12 |
6.968 |
2016 |
|
Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction.
|
Circ Heart Fail
27756791
|
22 |
6.372 |
2016 |
|
Procalcitonin: A new biomarker for the cardiologist.
|
Int J Cardiol
27543716
|
11 |
6.189 |
2016 |
|
Protein levels in Keap1-Nrf2 system in human failing heart.
|
Int J Cardiol
27710805
|
3 |
6.189 |
2016 |
|
Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia.
|
Int J Cardiol
27240157
|
4 |
6.189 |
2016 |
|
Development and validation of cardiovascular risk scores for haemodialysis patients.
|
Int J Cardiol
27140339
|
20 |
6.189 |
2016 |
|
Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life.
|
Int J Cardiol
27454614
|
87 |
6.189 |
2016 |
|
The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure.
|
Int J Cardiol
27288971
|
1 |
6.189 |
2016 |
|
Neuromuscular electrical stimulation for muscle wasting in heart failure patients.
|
Int J Cardiol
27728864
|
4 |
6.189 |
2016 |
|
Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.
|
Stroke
27354224
|
17 |
6.032 |
2016 |
|
Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure.
|
Am J Med
27401949
|
17 |
5.55 |
2016 |
|
Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF).
|
J Am Med Dir Assoc
27816483
|
27 |
5.325 |
2016 |
|
Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment.
|
J Card Fail
27867115
|
1 |
3.942 |
2016 |
|
Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
Circ J
27904018
|
12 |
3.544 |
2016 |
|
Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial.
|
Circ J
26804607
|
4 |
3.544 |
2016 |
|
Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.
|
Am J Cardiol
27015889
|
1 |
3.398 |
2016 |
|
Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.
|
Eur J Clin Pharmacol
26996442
|
5 |
2.902 |
2016 |
|
Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?
|
Aging Male
27650467
|
4 |
2.108 |
2016 |
|
Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study).
|
BMC Neurol
26793971
|
4 |
2.006 |
2016 |
|
Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study.
|
Cardiorenal Med
27994602
|
1 |
1.844 |
2016 |
|
Advances in cachexia and sarcopenia research in the heart failure context: call for action.
|
J Cardiovasc Med (Hagerstown)
27782931
|
1 |
1.613 |
2016 |
|
[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure].
|
Kardiol Pol
27748494
|
79 |
1.341 |
2016 |
|
Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure.
|
Wien Klin Wochenschr
27853883
|
18 |
0.974 |
2016 |
|
Publication trends in cachexia and sarcopenia in elderly heart failure patients.
|
Wien Klin Wochenschr
27885423
|
6 |
0.974 |
2016 |
|
The Syndrome of Heart Failure With Preserved Systolic Function.
|
Rev Esp Cardiol (Engl Ed)
27894772
|
0 |
0.181 |
2016 |
|
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
|
Rev Esp Cardiol (Engl Ed)
27894487
|
206 |
0.146 |
2016 |
|
Heart failure epidemiology and novel treatments in Japan: facts and numbers.
|
ESC Heart Fail
27840692
|
38 |
0 |
2016 |
|
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
|
Eur Heart J
26170468
|
27 |
20.212 |
2015 |
|
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium.
|
Eur Heart J
26170467
|
8 |
20.212 |
2015 |
|
Protective overweight in cardiovascular disease: moving from 'paradox' to 'paradigm'.
|
Eur Heart J
26341892
|
15 |
20.212 |
2015 |
|
Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.
|
Eur Heart J
25670819
|
19 |
20.212 |
2015 |
|
Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version.
|
Eur Heart J
25998514
|
39 |
20.212 |
2015 |
|
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
|
Eur Heart J
26082085
|
60 |
20.212 |
2015 |
|
Going Over LEGACY With a Pinch of Salt.
|
J Am Coll Cardiol
26493669
|
0 |
19.896 |
2015 |
|
Reply: Cardiovascular function and exercise capacity in patients with colorectal cancer: does anticancer therapy matter?
|
J Am Coll Cardiol
25835455
|
0 |
19.896 |
2015 |
|
Iron deficiency and cardiovascular disease.
|
Nat Rev Cardiol
26194551
|
93 |
14.299 |
2015 |
|
Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance.
|
Diabetes Care
25538323
|
4 |
11.857 |
2015 |
|
Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.
|
J Cachexia Sarcopenia Muscle
26675382
|
15 |
9.697 |
2015 |
|
More colour to the Journal: new style, new publisher, but still Cachexia, Sarcopenia and Muscle.
|
J Cachexia Sarcopenia Muscle
26136408
|
4 |
9.697 |
2015 |
|
Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation.
|
J Cachexia Sarcopenia Muscle
27066319
|
28 |
9.697 |
2015 |
|
Cachexia: a nutritional syndrome?
|
J Cachexia Sarcopenia Muscle
26675043
|
17 |
9.697 |
2015 |
|
Biomarkers for physical frailty and sarcopenia: state of the science and future developments.
|
J Cachexia Sarcopenia Muscle
26675566
|
89 |
9.697 |
2015 |
|
Influence of cancer cachexia on drug liver metabolism and renal elimination in rats.
|
J Cachexia Sarcopenia Muscle
26136411
|
18 |
9.697 |
2015 |
|
Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure.
|
J Cachexia Sarcopenia Muscle
26672973
|
10 |
9.697 |
2015 |
|
Febuxostat improves outcome in a rat model of cancer cachexia.
|
J Cachexia Sarcopenia Muscle
26136193
|
9 |
9.697 |
2015 |
|
Moving on up: the Journal of Cachexia, Sarcopenia and Muscle.
|
J Cachexia Sarcopenia Muscle
26401464
|
2 |
9.697 |
2015 |
|
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015.
|
J Cachexia Sarcopenia Muscle
26672494
|
172 |
9.697 |
2015 |
|
Request for regulatory guidance for cancer cachexia intervention trials.
|
J Cachexia Sarcopenia Muscle
26675232
|
57 |
9.697 |
2015 |
|
Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients.
|
J Am Soc Nephrol
26567245
|
37 |
8.966 |
2015 |
|
High cardiovascular event rates occur within the first weeks of starting hemodialysis.
|
Kidney Int
25923984
|
36 |
8.395 |
2015 |
|
Development and validation of a predictive mortality risk score from a European hemodialysis cohort.
|
Kidney Int
25651366
|
65 |
8.395 |
2015 |
|
One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure.
|
Eur J Heart Fail
26555602
|
53 |
6.968 |
2015 |
|
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
|
Eur J Heart Fail
25678098
|
30 |
6.968 |
2015 |
|
Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction.
|
Eur J Heart Fail
26198713
|
19 |
6.968 |
2015 |
|
Steps forward in regulatory pathways for acute and chronic heart failure.
|
Eur J Heart Fail
25597869
|
3 |
6.968 |
2015 |
|
What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative.
|
Eur J Heart Fail
26515299
|
12 |
6.968 |
2015 |
|
European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.
|
Eur J Heart Fail
26293171
|
13 |
6.968 |
2015 |
|
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
|
Eur J Heart Fail
25683972
|
32 |
6.968 |
2015 |
|
Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine.
|
Eur J Heart Fail
25999021
|
92 |
6.968 |
2015 |
|
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials.
|
Eur J Heart Fail
25704364
|
47 |
6.968 |
2015 |
|
In-hospital worsening heart failure.
|
Eur J Heart Fail
26235192
|
20 |
6.968 |
2015 |
|
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
|
Eur J Heart Fail
26011677
|
50 |
6.968 |
2015 |
|
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
|
Eur J Heart Fail
25919061
|
16 |
6.968 |
2015 |
|
Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
Eur J Heart Fail
26449626
|
23 |
6.968 |
2015 |
|
Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
|
Circ Heart Fail
25850425
|
4 |
6.833 |
2015 |
|
Ghrelin.
|
Mol Metab
26042199
|
353 |
6.799 |
2015 |
|
Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications.
|
Int J Cardiol
26318388
|
20 |
6.189 |
2015 |
|
In reply: Treatment of cachexia: An overview of recent developments.
|
Int J Cardiol
26313859
|
0 |
6.189 |
2015 |
|
PURE muscle and more.
|
Int J Cardiol
26433767
|
2 |
6.189 |
2015 |
|
Adaptive licensing - A way forward in the approval process of new therapeutic agents in Europe.
|
Int J Cardiol
25767018
|
1 |
6.189 |
2015 |
|
The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
|
Int J Cardiol
26705670
|
36 |
6.189 |
2015 |
|
Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure.
|
J Mol Cell Cardiol
26264758
|
6 |
5.68 |
2015 |
|
European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.
|
Europace
26297713
|
26 |
4.521 |
2015 |
|
EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
|
Eur Heart J Cardiovasc Imaging
25744342
|
10 |
4.293 |
2015 |
|
Developing models for cachexia and their implications in drug discovery.
|
Expert Opin Drug Discov
25927848
|
8 |
3.876 |
2015 |
|
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
|
Am J Cardiol
26189039
|
2 |
3.398 |
2015 |
|
The first prognostic model for stroke and death in patients with systolic heart failure.
|
J Cardiol
26549533
|
4 |
2.732 |
2015 |
|
Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.
|
Pharmacoepidemiol Drug Saf
26011775
|
5 |
2.552 |
2015 |
|
Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective.
|
Curr Opin Support Palliat Care
26509859
|
3 |
2.045 |
2015 |
|
PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial.
|
Trials
26041028
|
22 |
1.969 |
2015 |
|
Erratum to: PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial.
|
Trials
26204933
|
1 |
1.969 |
2015 |
|
Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure.
|
Croat Med J
26718759
|
2 |
1.619 |
2015 |
|
[Comments on the 2014 guidelines of the ESC/ESA: recommendations for the pre-operative assessment in non-cardiac surgery].
|
Dtsch Med Wochenschr
26069914
|
0 |
0.552 |
2015 |
|
A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
|
Rev Esp Cardiol (Engl Ed)
25649970
|
7 |
0.141 |
2015 |
|
Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure.
|
ESC Heart Fail
28834658
|
17 |
0 |
2015 |
|
Six1 is down-regulated in end-stage human dilated cardiomyopathy independently of Ezh2.
|
ESC Heart Fail
27668088
|
4 |
0 |
2015 |
|
Sleep-disordered breathing and cardiovascular disease.
|
Indian Heart J
27056657
|
6 |
0 |
2015 |
|
Steps forward in regulatory pathways for acute and chronic heart failure.
|
ESC Heart Fail
28834626
|
2 |
0 |
2015 |
|
Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges.
|
ESC Heart Fail
27708851
|
10 |
0 |
2015 |
|
Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy.
|
Pol Arch Med Wewn
25578437
|
2 |
0 |
2015 |
|
Improving care for patients with acute heart failure: before, during and after hospitalization.
|
ESC Heart Fail
28834628
|
88 |
0 |
2015 |
|
The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials.
|
Eur Heart J
24904027
|
120 |
20.212 |
2014 |
|
Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure.
|
Eur Heart J
24927731
|
69 |
20.212 |
2014 |
|
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
|
Eur Heart J
25086026
|
329 |
20.212 |
2014 |
|
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
|
Eur Heart J
25104786
|
124 |
20.212 |
2014 |
|
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
|
Eur Heart J
25176939
|
314 |
20.212 |
2014 |
|
How to determine a metabolically healthy body composition in cardiovascular disease.
|
J Am Coll Cardiol
25212653
|
0 |
19.896 |
2014 |
|
Metabolic impairment in heart failure: the myocardial and systemic perspective.
|
J Am Coll Cardiol
25257642
|
80 |
19.896 |
2014 |
|
Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry.
|
J Am Coll Cardiol
25169171
|
97 |
19.896 |
2014 |
|
Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia.
|
J Am Coll Cardiol
25212642
|
85 |
19.896 |
2014 |
|
Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer.
|
J Am Coll Cardiol
25257631
|
45 |
19.896 |
2014 |
|
Trials of implantable monitoring devices in heart failure: which design is optimal?
|
Nat Rev Cardiol
25113751
|
6 |
14.299 |
2014 |
|
Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention.
|
J Cachexia Sarcopenia Muscle
25192875
|
10 |
9.697 |
2014 |
|
Are we closer to having drugs to treat muscle wasting disease?
|
J Cachexia Sarcopenia Muscle
24865381
|
36 |
9.697 |
2014 |
|
Muscle wasting disease: a proposal for a new disease classification.
|
J Cachexia Sarcopenia Muscle
24595459
|
48 |
9.697 |
2014 |
|
Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies.
|
J Cachexia Sarcopenia Muscle
24595460
|
32 |
9.697 |
2014 |
|
Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.
|
J Cachexia Sarcopenia Muscle
25425503
|
208 |
9.697 |
2014 |
|
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014.
|
J Cachexia Sarcopenia Muscle
25384990
|
157 |
9.697 |
2014 |
|
From sarcopenia to frailty: a road less traveled.
|
J Cachexia Sarcopenia Muscle
24526568
|
47 |
9.697 |
2014 |
|
Formoterol in the treatment of experimental cancer cachexia: effects on heart function.
|
J Cachexia Sarcopenia Muscle
25167857
|
23 |
9.697 |
2014 |
|
Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial.
|
JACC Heart Fail
25453534
|
16 |
8.493 |
2014 |
|
Heart failure association of the European society of cardiology specialist heart failure curriculum.
|
Eur J Heart Fail
24464608
|
6 |
6.968 |
2014 |
|
Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failure association of the ESC.
|
Eur J Heart Fail
25175894
|
18 |
6.968 |
2014 |
|
Decongestion in acute heart failure.
|
Eur J Heart Fail
24599738
|
44 |
6.968 |
2014 |
|
High prevalence of iron deficiency in patients with acute decompensated heart failure.
|
Eur J Heart Fail
25065368
|
39 |
6.968 |
2014 |
|
Iron therapy in anaemic adults without chronic kidney disease.
|
Cochrane Database Syst Rev
25550190
|
16 |
6.264 |
2014 |
|
Racial differences in mortality in patients with advanced systolic heart failure: potential role of right ventricular ejection fraction.
|
Int J Cardiol
25499389
|
1 |
6.189 |
2014 |
|
Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy.
|
Int J Cardiol
25499388
|
2 |
6.189 |
2014 |
|
Treatment of cachexia: An overview of recent developments.
|
Int J Cardiol
25804188
|
24 |
6.189 |
2014 |
|
Bone marrow iron depletion is common in patients with coronary artery disease.
|
Int J Cardiol
25661858
|
14 |
6.189 |
2014 |
|
Current challenges for clinical trials of cardiovascular medical devices.
|
Int J Cardiol
24861254
|
7 |
6.189 |
2014 |
|
Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial.
|
Int J Cardiol
25456692
|
1 |
6.189 |
2014 |
|
Mitochondrial cytopathies and cardiovascular disease.
|
Heart
24449718
|
35 |
6.059 |
2014 |
|
Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia.
|
Stroke
25352483
|
38 |
6.032 |
2014 |
|
Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.
|
Circ Heart Fail
24737459
|
11 |
5.891 |
2014 |
|
Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction.
|
Circ Heart Fail
25296862
|
18 |
5.891 |
2014 |
|
Treatment of cachexia: an overview of recent developments.
|
J Am Med Dir Assoc
25455531
|
32 |
5.775 |
2014 |
|
Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.
|
Am J Med
25554369
|
19 |
5.55 |
2014 |
|
Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure.
|
Clin Res Cardiol
24990450
|
14 |
4.76 |
2014 |
|
European cardiac resynchronization therapy survey II: rationale and design.
|
Europace
25414481
|
5 |
4.521 |
2014 |
|
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.
|
Am Heart J
25066552
|
10 |
4.436 |
2014 |
|
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial.
|
J Card Fail
24530944
|
27 |
3.765 |
2014 |
|
Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
|
PLoS One
25426862
|
10 |
3.706 |
2014 |
|
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
|
Eur J Anaesthesiol
25127426
|
85 |
3.57 |
2014 |
|
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.
|
Heart Fail Rev
23099992
|
23 |
3.481 |
2014 |
|
ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.
|
Diab Vasc Dis Res
24800783
|
67 |
3.417 |
2014 |
|
Impact of atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults.
|
Am J Cardiol
25208562
|
9 |
3.398 |
2014 |
|
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
|
Cerebrovasc Dis
25300706
|
10 |
2.974 |
2014 |
|
Galectin-3: a modifiable risk factor in heart failure.
|
Cardiovasc Drugs Ther
24789662
|
31 |
2.82 |
2014 |
|
[Iron deficiency in chronic heart failure: from diagnosis to therapy].
|
Dtsch Med Wochenschr
24722935
|
1 |
0.552 |
2014 |
|
[2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment andmanagement].
|
Kardiol Pol
25524159
|
6 |
0.539 |
2014 |
|
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
|
ESC Heart Fail
28834668
|
16 |
0 |
2014 |
|
Research in acute and chronic heart failure is busier then ever worldwide and demands more publishing space: introducing ESC Heart Failure, the sister journal of the European Journal of Heart Failure.
|
ESC Heart Fail
28834670
|
1 |
0 |
2014 |
|
Heart failure: preventing disease and death worldwide.
|
ESC Heart Fail
28834669
|
374 |
0 |
2014 |
|
Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival.
|
ESC Heart Fail
28834667
|
2 |
0 |
2014 |
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
N Engl J Med
24206459
|
404 |
72.406 |
2013 |
|
Treatment of anemia with darbepoetin alfa in systolic heart failure.
|
N Engl J Med
23473338
|
135 |
72.406 |
2013 |
|
Tiotropium Respimat inhaler and the risk of death in COPD.
|
N Engl J Med
23992515
|
133 |
72.406 |
2013 |
|
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
|
JAMA
23443441
|
252 |
44.405 |
2013 |
|
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
|
Eur Heart J
23990596
|
88 |
20.212 |
2013 |
|
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
|
Eur Heart J
23996285
|
621 |
20.212 |
2013 |
|
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.
|
Eur Heart J
23592708
|
54 |
20.212 |
2013 |
|
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
Eur Heart J
23771844
|
1406 |
20.212 |
2013 |
|
Cardiac hepatopathy versus end-stage liver disease: two different entities.
|
J Am Coll Cardiol
24315902
|
2 |
19.896 |
2013 |
|
Iron status and survival in diabetic patients with coronary artery disease.
|
Diabetes Care
24130349
|
26 |
11.857 |
2013 |
|
Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS).
|
J Cachexia Sarcopenia Muscle
23483531
|
13 |
9.697 |
2013 |
|
Why cachexia kills: examining the causality of poor outcomes in wasting conditions.
|
J Cachexia Sarcopenia Muscle
23749718
|
62 |
9.697 |
2013 |
|
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats.
|
J Cachexia Sarcopenia Muscle
24272787
|
25 |
9.697 |
2013 |
|
Cachexia vs obesity: where is the real unmet clinical need?
|
J Cachexia Sarcopenia Muscle
24197816
|
8 |
9.697 |
2013 |
|
Relation of respiratory muscle strength, cachexia and survival in severe chronic heart failure.
|
J Cachexia Sarcopenia Muscle
23794292
|
11 |
9.697 |
2013 |
|
Cachexia as a major public health problem: frequent, costly, and deadly.
|
J Cachexia Sarcopenia Muscle
23539127
|
65 |
9.697 |
2013 |
|
Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure).
|
JACC Heart Fail
24621869
|
44 |
8.493 |
2013 |
|
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
|
Eur J Heart Fail
23787718
|
82 |
6.968 |
2013 |
|
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.
|
Eur J Heart Fail
23355060
|
30 |
6.968 |
2013 |
|
The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
|
Eur J Heart Fail
23639779
|
9 |
6.968 |
2013 |
|
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.
|
Eur J Heart Fail
23787723
|
27 |
6.968 |
2013 |
|
Increased catabolic activity in adipose tissue of patients with chronic heart failure.
|
Eur J Heart Fail
23696611
|
19 |
6.968 |
2013 |
|
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
|
Eur J Heart Fail
23978433
|
171 |
6.968 |
2013 |
|
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
|
Eur J Heart Fail
23787722
|
57 |
6.968 |
2013 |
|
Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain.
|
CMAJ
23509133
|
5 |
6.784 |
2013 |
|
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
|
Int J Cardiol
23870642
|
8 |
6.189 |
2013 |
|
Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia.
|
Int J Cardiol
23680591
|
17 |
6.189 |
2013 |
|
Frailty and heart disease.
|
Int J Cardiol
23931976
|
20 |
6.189 |
2013 |
|
TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy.
|
Int J Cardiol
23360823
|
25 |
6.189 |
2013 |
|
Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction.
|
Int J Cardiol
23347612
|
42 |
6.189 |
2013 |
|
Cardiac cachexia is associated with right ventricular failure and liver dysfunction.
|
Int J Cardiol
24063924
|
16 |
6.189 |
2013 |
|
The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy.
|
Int J Cardiol
23751350
|
12 |
6.189 |
2013 |
|
Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure.
|
Int J Cardiol
24405838
|
6 |
6.189 |
2013 |
|
Stroke induced Sarcopenia: muscle wasting and disability after stroke.
|
Int J Cardiol
24231058
|
92 |
6.189 |
2013 |
|
Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study.
|
Int J Cardiol
23731526
|
24 |
6.189 |
2013 |
|
Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
|
Int J Cardiol
23968714
|
20 |
6.189 |
2013 |
|
Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia.
|
Int J Cardiol
24207070
|
8 |
6.189 |
2013 |
|
Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model.
|
Int J Cardiol
23465234
|
8 |
6.189 |
2013 |
|
Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events.
|
Int J Cardiol
23380700
|
12 |
6.189 |
2013 |
|
Tele-accelerometry as a novel technique for assessing functional status in patients with heart failure: feasibility, reliability and patient safety.
|
Int J Cardiol
23962782
|
18 |
6.189 |
2013 |
|
Aerobic training in adults after atrial switch procedure for transposition of the great arteries improves exercise capacity without impairing systemic right ventricular function.
|
Int J Cardiol
24207068
|
8 |
6.189 |
2013 |
|
Orthostatic hypotension and incident heart failure in community-dwelling older adults.
|
J Gerontol A Biol Sci Med Sci
23846416
|
13 |
5.957 |
2013 |
|
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.
|
Circ Heart Fail
23881846
|
9 |
5.945 |
2013 |
|
Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF).
|
J Am Med Dir Assoc
24094897
|
11 |
5.775 |
2013 |
|
Frailty consensus: a call to action.
|
J Am Med Dir Assoc
23764209
|
1066 |
5.775 |
2013 |
|
Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure.
|
Am J Med
24257326
|
29 |
5.55 |
2013 |
|
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.
|
Am J Med
23490060
|
19 |
5.55 |
2013 |
|
Pharmacokinetics of drugs in cachectic patients: a systematic review.
|
PLoS One
24282510
|
32 |
4.034 |
2013 |
|
Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis.
|
Nutr Metab Cardiovasc Dis
23791298
|
31 |
3.679 |
2013 |
|
Muscle wasting in heart failure: An overview.
|
Int J Biochem Cell Biol
23665153
|
47 |
3.505 |
2013 |
|
Mechanism and novel therapeutic approaches to wasting in chronic disease.
|
Maturitas
23664695
|
21 |
3.255 |
2013 |
|
Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.
|
Nutrition
24976415
|
6 |
3.099 |
2013 |
|
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
|
Cerebrovasc Dis
23921215
|
3 |
2.974 |
2013 |
|
Relation of impaired interorgan communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome.
|
J Crit Care
24529299
|
5 |
2.648 |
2013 |
|
The role of micronutrients and macronutrients in patients hospitalized for heart failure.
|
Heart Fail Clin
23809420
|
4 |
2.124 |
2013 |
|
Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study.
|
Arch Med Sci
23671436
|
5 |
1.969 |
2013 |
|
Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
|
Arch Med Sci
23515589
|
13 |
1.969 |
2013 |
|
Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?
|
Aging Male
23803163
|
1 |
1.85 |
2013 |
|
[Treatment of chronic systolic heart failure].
|
Dtsch Med Wochenschr
23884736
|
0 |
0.552 |
2013 |
|
[ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].
|
Kardiol Pol
24297732
|
2 |
0.519 |
2013 |
|
Andropausal syndrome in men with systolic heart failure.
|
Pol Arch Med Wewn
23449158
|
3 |
0 |
2013 |
|
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
|
N Engl J Med
23126252
|
673 |
72.406 |
2012 |
|
Warfarin and aspirin in patients with heart failure and sinus rhythm.
|
N Engl J Med
22551105
|
149 |
72.406 |
2012 |
|
Vitamin D in chronic kidney disease: more questions than answers.
|
JAMA
22337683
|
5 |
44.405 |
2012 |
|
Does obesity make it better or worse: insights into cardiovascular illnesses.
|
Eur Heart J
22947611
|
4 |
20.212 |
2012 |
|
Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?
|
Eur Heart J
22927554
|
26 |
20.212 |
2012 |
|
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF).
|
Eur Heart J
23178647
|
196 |
20.212 |
2012 |
|
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
|
Eur Heart J
22297124
|
59 |
20.212 |
2012 |
|
Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial.
|
Eur Heart J
23076781
|
74 |
20.212 |
2012 |
|
Iron status in patients with chronic heart failure.
|
Eur Heart J
23178646
|
61 |
20.212 |
2012 |
|
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
|
Eur Heart J
22611136
|
1472 |
20.212 |
2012 |
|
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives.
|
Eur Heart J
23100285
|
116 |
20.212 |
2012 |
|
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial.
|
J Am Coll Cardiol
22300693
|
35 |
19.896 |
2012 |
|
Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.
|
J Cachexia Sarcopenia Muscle
22460618
|
12 |
9.697 |
2012 |
|
Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model.
|
J Cachexia Sarcopenia Muscle
22987245
|
20 |
9.697 |
2012 |
|
The obesity paradox in chronic disease: facts and numbers.
|
J Cachexia Sarcopenia Muscle
22450395
|
49 |
9.697 |
2012 |
|
Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.
|
J Cachexia Sarcopenia Muscle
22865205
|
113 |
9.697 |
2012 |
|
From muscle wasting to sarcopenia and myopenia: update 2012.
|
J Cachexia Sarcopenia Muscle
23160774
|
58 |
9.697 |
2012 |
|
Erratum to: Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.
|
J Cachexia Sarcopenia Muscle
22614821
|
0 |
9.697 |
2012 |
|
The relevance of congestion in the cardio-renal syndrome.
|
Kidney Int
23254894
|
38 |
8.395 |
2012 |
|
Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
|
Eur J Heart Fail
22302662
|
38 |
6.968 |
2012 |
|
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study.
|
Eur J Heart Fail
22764184
|
38 |
6.968 |
2012 |
|
Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
|
Eur J Heart Fail
22689292
|
19 |
6.968 |
2012 |
|
Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
|
Eur J Heart Fail
22611046
|
24 |
6.968 |
2012 |
|
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
|
Eur J Heart Fail
22828712
|
900 |
6.968 |
2012 |
|
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency.
|
Eur J Heart Fail
22523375
|
22 |
6.968 |
2012 |
|
Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia.
|
Int J Cancer
22336965
|
26 |
6.513 |
2012 |
|
Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease.
|
Int J Cardiol
22668800
|
24 |
6.189 |
2012 |
|
Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure--insight from the Cardiac Insufficiency Bisoprolol Study in Elderly.
|
Int J Cardiol
22726401
|
3 |
6.189 |
2012 |
|
Muscle in heart disease: highlights from the European Society of Cardiology's Annual Meeting 2012.
|
Int J Cardiol
23121913
|
1 |
6.189 |
2012 |
|
Anaemia predicts health related quality of life in heart failure patients.
|
Int J Cardiol
23127613
|
1 |
6.189 |
2012 |
|
No train, no gain: does this apply to heart failure with preserved ejection fraction?
|
Int J Cardiol
23121915
|
1 |
6.189 |
2012 |
|
Cachexia as major underestimated unmet medical need: facts and numbers.
|
Int J Cardiol
23084543
|
17 |
6.189 |
2012 |
|
Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.
|
Int J Cardiol
21856022
|
4 |
6.189 |
2012 |
|
Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
|
Int J Cardiol
23174169
|
10 |
6.189 |
2012 |
|
Liver metabolism in cardiac cachexia.
|
Int J Cardiol
23122623
|
0 |
6.189 |
2012 |
|
Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection.
|
Int J Cardiol
23017815
|
10 |
6.189 |
2012 |
|
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
|
Thromb Haemost
23093044
|
24 |
5.627 |
2012 |
|
Assessment of serum cotinine in patients with chronic heart failure: self-reported versus objective smoking behaviour.
|
Clin Res Cardiol
22878732
|
3 |
4.76 |
2012 |
|
Role of iron deficiency and anemia in cardio-renal syndromes.
|
Semin Nephrol
22365163
|
5 |
3.598 |
2012 |
|
Anemia in chronic heart failure: can we treat? What to treat?
|
Heart Fail Rev
21979835
|
15 |
3.481 |
2012 |
|
STRoke Adverse outcome is associated WIth NoSocomial Infections (STRAWINSKI): procalcitonin ultrasensitive-guided antibacterial therapy in severe ischaemic stroke patients - rationale and protocol for a randomized controlled trial.
|
Int J Stroke
22925000
|
4 |
3.314 |
2012 |
|
Liver dysfunction and its nutritional implications in heart failure.
|
Nutrition
23022119
|
16 |
3.146 |
2012 |
|
Theophylline is able to partially revert cachexia in tumour-bearing rats.
|
Nutr Metab (Lond)
22909172
|
13 |
2.974 |
2012 |
|
The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea.
|
Biomarkers
22616939
|
1 |
2.006 |
2012 |
|
Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial.
|
Emerg Med J
22962091
|
3 |
1.861 |
2012 |
|
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012].
|
Turk Kardiyol Dern Ars
27305718
|
11 |
0.277 |
2012 |
|
[Commentary on the 2010 ESC guidelines on device therapy in heart failure ].
|
Herzschrittmacherther Elektrophysiol
22456701
|
0 |
0 |
2012 |
|
Erythropoietin in kidney disease and type 2 diabetes.
|
N Engl J Med
21268744
|
0 |
72.406 |
2011 |
|
Effect of nesiritide in patients with acute decompensated heart failure.
|
N Engl J Med
21732835
|
386 |
72.406 |
2011 |
|
Definition and classification of cancer cachexia: an international consensus.
|
Lancet Oncol
21296615
|
1701 |
33.9 |
2011 |
|
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology.
|
Eur Heart J
21572115
|
16 |
20.212 |
2011 |
|
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
|
Eur Heart J
21208974
|
133 |
20.212 |
2011 |
|
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.
|
Eur Heart J
21199831
|
53 |
20.212 |
2011 |
|
Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
|
J Am Coll Cardiol
21867843
|
39 |
19.896 |
2011 |
|
Limitations of gait speed as an independent predictor of mortality and morbidity in cardiac patients.
|
J Am Coll Cardiol
21816319
|
0 |
19.896 |
2011 |
|
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study.
|
Circulation
21444883
|
234 |
19.309 |
2011 |
|
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.
|
Nat Rev Cardiol
21629210
|
63 |
14.299 |
2011 |
|
The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area.
|
J Cachexia Sarcopenia Muscle
22207906
|
2 |
9.697 |
2011 |
|
Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia.
|
J Cachexia Sarcopenia Muscle
22207907
|
24 |
9.697 |
2011 |
|
IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.
|
J Cachexia Sarcopenia Muscle
21766056
|
25 |
9.697 |
2011 |
|
Myopenia-a new universal term for muscle wasting.
|
J Cachexia Sarcopenia Muscle
21475620
|
49 |
9.697 |
2011 |
|
Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle.
|
J Cachexia Sarcopenia Muscle
21966640
|
14 |
9.697 |
2011 |
|
The role of myostatin in muscle wasting: an overview.
|
J Cachexia Sarcopenia Muscle
21966641
|
145 |
9.697 |
2011 |
|
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design.
|
J Cachexia Sarcopenia Muscle
22207908
|
27 |
9.697 |
2011 |
|
Ursodeoxycholic acid treatment in a rat model of cancer cachexia.
|
J Cachexia Sarcopenia Muscle
22450540
|
12 |
9.697 |
2011 |
|
Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.
|
J Cachexia Sarcopenia Muscle
21766053
|
49 |
9.697 |
2011 |
|
Cachexia in heart disease: highlights from the ESC 2010.
|
J Cachexia Sarcopenia Muscle
21475672
|
12 |
9.697 |
2011 |
|
The obesity paradox in heart failure: accepting reality and making rational decisions.
|
Clin Pharmacol Ther
21654743
|
16 |
7.266 |
2011 |
|
Telemedicine and remote management of patients with heart failure.
|
Lancet
21856487
|
94 |
7.133 |
2011 |
|
Revisiting the obesity paradox in heart failure: new insights?
|
Eur J Heart Fail
21262928
|
2 |
6.968 |
2011 |
|
Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study.
|
Eur J Heart Fail
22140234
|
19 |
6.968 |
2011 |
|
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
|
Eur J Heart Fail
21429992
|
51 |
6.968 |
2011 |
|
Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study.
|
Eur J Heart Fail
21613429
|
25 |
6.968 |
2011 |
|
Predictors of clinical outcomes in elderly patients with heart failure.
|
Eur J Heart Fail
21454299
|
39 |
6.968 |
2011 |
|
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
21169385
|
142 |
6.968 |
2011 |
|
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation.
|
Eur J Heart Fail
21436360
|
191 |
6.968 |
2011 |
|
High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients.
|
Am J Clin Nutr
21813809
|
26 |
6.926 |
2011 |
|
Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.
|
Circ Heart Fail
21765124
|
58 |
6.286 |
2011 |
|
Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly.
|
Int J Cardiol
22133470
|
6 |
6.189 |
2011 |
|
Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction.
|
Int J Cardiol
22197217
|
14 |
6.189 |
2011 |
|
Furosemide induces mortality in a rat model of chronic heart failure.
|
Int J Cardiol
21450356
|
5 |
6.189 |
2011 |
|
Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries.
|
Int J Cardiol
22188991
|
25 |
6.189 |
2011 |
|
Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction.
|
Int J Cardiol
21821297
|
10 |
6.189 |
2011 |
|
Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis.
|
Int J Cardiol
22192286
|
9 |
6.189 |
2011 |
|
Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis.
|
Int J Cardiol
21652093
|
2 |
6.189 |
2011 |
|
Self-reported teenage body size and heart failure in adults ≥65years of age.
|
Int J Cardiol
21470704
|
0 |
6.189 |
2011 |
|
Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trial.
|
Int J Cardiol
21982700
|
43 |
6.189 |
2011 |
|
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
|
Int J Cardiol
22037349
|
84 |
6.189 |
2011 |
|
Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction.
|
Heart
21415071
|
26 |
6.059 |
2011 |
|
Sarcopenia with limited mobility: an international consensus.
|
J Am Med Dir Assoc
21640657
|
337 |
5.775 |
2011 |
|
Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction.
|
Clin Res Cardiol
21766239
|
24 |
4.76 |
2011 |
|
Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1.
|
PLoS One
21264211
|
16 |
4.641 |
2011 |
|
Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.
|
PLoS One
22102869
|
18 |
4.641 |
2011 |
|
Low plasma triiodothyronine levels in heart failure are associated with a reduced anabolic state and membrane damage.
|
Eur J Endocrinol
21454442
|
1 |
4.101 |
2011 |
|
Heart failure is a risk factor for incident driving cessation among community-dwelling older adults: findings from a prospective population study.
|
J Card Fail
22123368
|
3 |
3.765 |
2011 |
|
Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.
|
J Card Fail
22041326
|
74 |
3.765 |
2011 |
|
Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease.
|
Respir Med
22015080
|
9 |
3.217 |
2011 |
|
Short-term mortality risk in emergency department acute heart failure.
|
Acad Emerg Med
21906204
|
20 |
2.925 |
2011 |
|
Gender related issues in the management of heart failure.
|
Curr Pharm Des
21449888
|
0 |
2.611 |
2011 |
|
Muscle metabolism and exercise capacity in cachexia.
|
Curr Pharm Des
21933139
|
3 |
2.611 |
2011 |
|
Relationship between stage of kidney disease and incident heart failure in older adults.
|
Am J Nephrol
21734366
|
3 |
2.539 |
2011 |
|
The effects of bilateral lung transplantation on ventilatory efficiency, oxygen uptake and the right heart: a two-yr follow-up.
|
Clin Transplant
20637037
|
3 |
1.865 |
2011 |
|
Cardio-renal anemia syndrome.
|
Contrib Nephrol
21625123
|
4 |
1.487 |
2011 |
|
Anemia in heart failure: an overview of current concepts.
|
Future Cardiol
21174515
|
3 |
1.464 |
2011 |
|
Adherence to treatment guidelines and long-term survival in hospitalized patients with chronic obstructive pulmonary disease.
|
J Eval Clin Pract
21223458
|
13 |
1.25 |
2011 |
|
Hormonal consequences and prognosis of chronic heart failure.
|
Curr Opin Endocrinol Diabetes Obes
21494135
|
11 |
0 |
2011 |
|
Systolic heart failure.
|
N Engl J Med
20414982
|
0 |
72.406 |
2010 |
|
2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.
|
Eur Heart J
20801924
|
113 |
20.212 |
2010 |
|
Iron deficiency: an ominous sign in patients with systolic chronic heart failure.
|
Eur Heart J
20570952
|
175 |
20.212 |
2010 |
|
A single dose of erythropoietin in ST-elevation myocardial infarction.
|
Eur Heart J
20802250
|
49 |
20.212 |
2010 |
|
The BALANCE study too early to speculate on mortality effects.
|
J Am Coll Cardiol
20117418
|
0 |
19.896 |
2010 |
|
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
|
J Am Coll Cardiol
20447528
|
136 |
19.896 |
2010 |
|
Battlescarred: subgroup or selection bias?
|
J Am Coll Cardiol
20951331
|
0 |
19.896 |
2010 |
|
Myostatin: Regulator of muscle wasting in heart failure and treatment target for cardiac cachexia.
|
Circulation
20065169
|
4 |
19.309 |
2010 |
|
MicroRNAs as circulating biomarkers for heart failure: questions about MiR-423-5p.
|
Circ Res
20466983
|
13 |
13.965 |
2010 |
|
An overview of sarcopenia: facts and numbers on prevalence and clinical impact.
|
J Cachexia Sarcopenia Muscle
21475695
|
292 |
9.697 |
2010 |
|
Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
J Cachexia Sarcopenia Muscle
21475696
|
29 |
9.697 |
2010 |
|
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
|
J Cachexia Sarcopenia Muscle
21475697
|
87 |
9.697 |
2010 |
|
The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study.
|
J Cachexia Sarcopenia Muscle
21475692
|
56 |
9.697 |
2010 |
|
Cachexia as a major underestimated and unmet medical need: facts and numbers.
|
J Cachexia Sarcopenia Muscle
21475699
|
184 |
9.697 |
2010 |
|
Hemoglobin variability does not predict mortality in European hemodialysis patients.
|
J Am Soc Nephrol
20798262
|
22 |
8.966 |
2010 |
|
Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol.
|
Clin Pharmacol Ther
20827268
|
13 |
7.266 |
2010 |
|
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study.
|
Eur J Heart Fail
20930001
|
36 |
6.968 |
2010 |
|
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine.
|
Eur J Heart Fail
20354029
|
215 |
6.968 |
2010 |
|
Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design.
|
Eur J Heart Fail
21098580
|
53 |
6.968 |
2010 |
|
Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age.
|
Eur J Heart Fail
20354030
|
13 |
6.968 |
2010 |
|
Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.
|
Eur J Heart Fail
20215339
|
43 |
6.968 |
2010 |
|
2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.
|
Eur J Heart Fail
20965877
|
44 |
6.968 |
2010 |
|
Liraglutide for weight loss in obese people.
|
Lancet
20159285
|
1 |
6.79 |
2010 |
|
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis.
|
Mayo Clin Proc
21037042
|
135 |
6.686 |
2010 |
|
Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
|
Int J Cardiol
20561693
|
7 |
6.189 |
2010 |
|
A new telemonitoring system intended for chronic heart failure patients using mobile telephone technology--feasibility study.
|
Int J Cardiol
20851481
|
23 |
6.189 |
2010 |
|
Absolute and functional iron deficiency in professional athletes during training and recovery.
|
Int J Cardiol
21145121
|
28 |
6.189 |
2010 |
|
The small intestine: a critical linkage in pathophysiology of cardiac cachexia.
|
Int J Cardiol
21112652
|
7 |
6.189 |
2010 |
|
Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease.
|
Int J Cardiol
21159392
|
13 |
6.189 |
2010 |
|
Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure.
|
Int J Cardiol
21190739
|
79 |
6.189 |
2010 |
|
Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters.
|
Int J Cardiol
21093941
|
7 |
6.189 |
2010 |
|
Consensus on cachexia definitions.
|
J Am Med Dir Assoc
20439040
|
44 |
5.775 |
2010 |
|
Nutritional recommendations for the management of sarcopenia.
|
J Am Med Dir Assoc
20627179
|
177 |
5.775 |
2010 |
|
Anaemia is an independent predictor of death in patients hospitalized for acute heart failure.
|
Clin Res Cardiol
19921298
|
18 |
4.76 |
2010 |
|
Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics".
|
Clin Nutr
20060626
|
503 |
4.548 |
2010 |
|
2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.
|
Europace
20974767
|
46 |
4.521 |
2010 |
|
Possible interactive effect of testosterone and aldosterone receptor antagonists on cardiac apoptosis.
|
Rev Esp Cardiol
20609308
|
1 |
4.485 |
2010 |
|
ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.
|
Nephrol Dial Transplant
20494894
|
8 |
4.47 |
2010 |
|
Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference.
|
Nephrol Dial Transplant
20375030
|
9 |
4.47 |
2010 |
|
Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference.
|
Nephrol Dial Transplant
20185818
|
65 |
4.47 |
2010 |
|
Biomarkers in kidney and heart disease.
|
Nephrol Dial Transplant
20978142
|
18 |
4.47 |
2010 |
|
Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference.
|
Nephrol Dial Transplant
20228069
|
53 |
4.47 |
2010 |
|
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.
|
Nephrol Dial Transplant
20466670
|
164 |
4.47 |
2010 |
|
Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure.
|
Circ Heart Fail
20233990
|
9 |
4.315 |
2010 |
|
Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference.
|
Expert Opin Investig Drugs
20367196
|
20 |
4.03 |
2010 |
|
Losartan: the dose does it.
|
Expert Opin Pharmacother
20497092
|
0 |
3.894 |
2010 |
|
The underestimated impact of cachexia.
|
Expert Opin Drug Discov
22823967
|
1 |
3.876 |
2010 |
|
In vivo models of cardiac diseases: application to drug development and screening.
|
Expert Opin Drug Discov
22823972
|
1 |
3.876 |
2010 |
|
Action profile of the antiobesity drug candidate oleoyl-estrone in rats.
|
Obesity (Silver Spring)
20339368
|
3 |
3.873 |
2010 |
|
Anaerobic threshold: teaching material and not prognostic parameter.
|
J Card Fail
20447583
|
0 |
3.765 |
2010 |
|
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).
|
Eur J Anaesthesiol
20068416
|
37 |
3.57 |
2010 |
|
Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study).
|
Am J Cardiol
20346316
|
10 |
3.398 |
2010 |
|
Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]).
|
Am J Cardiol
20609652
|
15 |
3.398 |
2010 |
|
Treatment with iron of patients with heart failure with and without anemia.
|
Heart Fail Clin
20630405
|
3 |
2.124 |
2010 |
|
Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI).
|
Contrib Nephrol
20427956
|
35 |
1.274 |
2010 |
|
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
|
Contrib Nephrol
20427964
|
3 |
1.274 |
2010 |
|
Management of chronic cardiorenal syndrome.
|
Contrib Nephrol
20427962
|
2 |
1.274 |
2010 |
|
An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study.
|
Nephron Clin Pract
21150222
|
13 |
0 |
2010 |
|
Ferric carboxymaltose in patients with heart failure and iron deficiency.
|
N Engl J Med
19920054
|
542 |
72.406 |
2009 |
|
Circulating estradiol and mortality in men with systolic chronic heart failure.
|
JAMA
19436016
|
32 |
44.405 |
2009 |
|
The obesity paradox: weighing the benefit.
|
Eur Heart J
19734553
|
40 |
20.212 |
2009 |
|
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative.
|
Eur Heart J
20037146
|
290 |
20.212 |
2009 |
|
Smoking cessation in heart failure: easier said than done.
|
Eur Heart J
19147606
|
0 |
20.212 |
2009 |
|
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery.
|
Eur Heart J
19713421
|
125 |
20.212 |
2009 |
|
Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.
|
Eur Heart J
19383732
|
34 |
20.212 |
2009 |
|
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
|
Eur Heart J
19346228
|
72 |
20.212 |
2009 |
|
Renal protective effects and prevention of contrast-induced nephropathy by atrial natriuretic peptide can it work?
|
J Am Coll Cardiol
19761946
|
0 |
19.896 |
2009 |
|
Beta-blockers in elderly patients with heart failure ready for prime time?
|
J Am Coll Cardiol
19942096
|
1 |
19.896 |
2009 |
|
Micronutrient deficiencies an unmet need in heart failure.
|
J Am Coll Cardiol
19850206
|
42 |
19.896 |
2009 |
|
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
|
J Am Coll Cardiol
19497441
|
113 |
19.896 |
2009 |
|
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association.
|
Circulation
19720935
|
233 |
19.309 |
2009 |
|
Body mass, chronic heart failure, surgery and survival.
|
J Heart Lung Transplant
19837608
|
2 |
7.114 |
2009 |
|
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
19386813
|
119 |
6.968 |
2009 |
|
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.
|
Eur J Heart Fail
19633103
|
27 |
6.968 |
2009 |
|
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure.
|
Eur J Heart Fail
19815661
|
5 |
6.968 |
2009 |
|
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
19168509
|
123 |
6.968 |
2009 |
|
Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
|
Eur J Heart Fail
19875408
|
34 |
6.968 |
2009 |
|
The influence of age and sex on disease development in a novel animal model of cardiac cachexia.
|
Int J Cardiol
19246111
|
11 |
6.189 |
2009 |
|
Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers.
|
Int J Cardiol
19144431
|
19 |
6.189 |
2009 |
|
Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension.
|
Int J Cardiol
19411119
|
15 |
6.189 |
2009 |
|
Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure.
|
Int J Cardiol
19733925
|
10 |
6.189 |
2009 |
|
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.
|
Int J Cardiol
19201041
|
48 |
6.189 |
2009 |
|
The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure.
|
Int J Cardiol
19155075
|
18 |
6.189 |
2009 |
|
A network against failing hearts--introducing the German "Competence Network Heart Failure".
|
Int J Cardiol
19679361
|
21 |
6.189 |
2009 |
|
Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients.
|
Am J Transplant
19845589
|
10 |
6.165 |
2009 |
|
C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure.
|
Clin Sci (Lond)
19450232
|
4 |
4.936 |
2009 |
|
Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure.
|
PLoS One
19641622
|
14 |
4.687 |
2009 |
|
ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology.
|
Clin Nutr
19515464
|
14 |
4.548 |
2009 |
|
Exercise capacity and body composition in living-donor renal transplant recipients over time.
|
Nephrol Dial Transplant
19736242
|
11 |
4.47 |
2009 |
|
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
|
Circ Heart Fail
19933411
|
59 |
4.315 |
2009 |
|
Nutrition in heart failure: an update.
|
Curr Opin Clin Nutr Metab Care
19474718
|
16 |
4.023 |
2009 |
|
The gut and intestinal bacteria in chronic heart failure.
|
Curr Drug Metab
19149510
|
32 |
3.896 |
2009 |
|
Overview of emerging pharmacotherapy in chronic heart failure.
|
Expert Opin Pharmacother
19606938
|
0 |
3.894 |
2009 |
|
Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure.
|
J Card Fail
19477405
|
34 |
3.765 |
2009 |
|
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
|
J Card Fail
19643369
|
0 |
3.765 |
2009 |
|
The influence of recovery and training phases on body composition, peripheral vascular function and immune system of professional soccer players.
|
PLoS One
19293937
|
19 |
2.806 |
2009 |
|
Cachexia and aging: an update based on the Fourth International Cachexia Meeting.
|
J Nutr Health Aging
19151908
|
22 |
2.484 |
2009 |
|
Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders.
|
Heart Fail Clin
19631179
|
36 |
2.124 |
2009 |
|
The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure.
|
Wien Klin Wochenschr
19562292
|
23 |
0.974 |
2009 |
|
Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review.
|
Wien Klin Wochenschr
19562289
|
11 |
0.974 |
2009 |
|
Elevated TNFalpha production in whole blood in patients with severe COPD: the potential link to disease severity.
|
Wien Klin Wochenschr
19562291
|
9 |
0.974 |
2009 |
|
Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges.
|
Herz
20024637
|
10 |
0.776 |
2009 |
|
Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems.
|
Herz
19370331
|
14 |
0.776 |
2009 |
|
Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients.
|
NDT Plus
19461857
|
1 |
0 |
2009 |
|
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
|
Eur Heart J
18819960
|
60 |
20.212 |
2008 |
|
Insulin resistance in chronic heart failure.
|
J Am Coll Cardiol
18617075
|
6 |
19.896 |
2008 |
|
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
|
J Am Coll Cardiol
18191732
|
155 |
19.896 |
2008 |
|
Cardiac cachexia: a systematic overview.
|
Pharmacol Ther
19061914
|
123 |
11.127 |
2008 |
|
Clenbuterol impairs muscle quality and is potentially dangerous.
|
J Heart Lung Transplant
18656813
|
0 |
7.114 |
2008 |
|
Uric acid in chronic heart failure--current pathophysiological concepts.
|
Eur J Heart Fail
19008148
|
2 |
6.968 |
2008 |
|
State of the art: using natriuretic peptide levels in clinical practice.
|
Eur J Heart Fail
18760965
|
225 |
6.968 |
2008 |
|
Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure.
|
Eur J Heart Fail
18760666
|
11 |
6.968 |
2008 |
|
Reversibility of cachexia after bilateral lung transplantation.
|
Int J Cardiol
18234375
|
5 |
6.189 |
2008 |
|
A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure.
|
Int J Cardiol
18691778
|
15 |
6.189 |
2008 |
|
No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure.
|
Int J Cardiol
18723230
|
17 |
6.189 |
2008 |
|
Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition.
|
Int J Cardiol
18778861
|
15 |
6.189 |
2008 |
|
Atrial fibrillation in chronic non-cardiac disease: where do we stand?
|
Int J Cardiol
18374999
|
19 |
6.189 |
2008 |
|
The mechanism of assembly and cofactor insertion into Rhodobacter capsulatus xanthine dehydrogenase.
|
J Biol Chem
18390908
|
17 |
5.328 |
2008 |
|
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.
|
Lancet
18207018
|
58 |
5.203 |
2008 |
|
Beta blockers and glucose metabolism in chronic heart failure: friend or foe?
|
Clin Res Cardiol
18026703
|
4 |
4.76 |
2008 |
|
Cachexia: a new definition.
|
Clin Nutr
18718696
|
776 |
4.548 |
2008 |
|
Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
|
Am Heart J
19081402
|
2 |
4.436 |
2008 |
|
Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III).
|
Am Heart J
18440327
|
14 |
4.436 |
2008 |
|
Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats.
|
Am J Physiol Endocrinol Metab
18460598
|
29 |
4.142 |
2008 |
|
The emerging role of the gut in chronic heart failure.
|
Curr Opin Clin Nutr Metab Care
18685461
|
49 |
4.023 |
2008 |
|
Nutritional and anti-inflammatory interventions in chronic heart failure.
|
Am J Cardiol
18514634
|
54 |
3.398 |
2008 |
|
Cachexia: common, deadly, with an urgent need for precise definition and new therapies.
|
Am J Cardiol
18514632
|
25 |
3.398 |
2008 |
|
Nutritional supplementation with amino acids in cardiovascular and metabolic diseases: hypermetabolic syndrome as a therapeutic target. Introduction.
|
Am J Cardiol
18514617
|
0 |
3.398 |
2008 |
|
A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure.
|
Am J Cardiol
18549857
|
11 |
3.398 |
2008 |
|
The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond.
|
Heart Fail Clin
18433694
|
4 |
2.124 |
2008 |
|
Anticoagulants, antiplatelets, and statins in heart failure.
|
Cardiol Clin
18312905
|
2 |
1.36 |
2008 |
|
Are diuretics overused in the treatment of chronic heart failure?
|
Nat Clin Pract Cardiovasc Med
18268513
|
1 |
0 |
2008 |
|
Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards onco-cardiology.
|
Nat Clin Pract Oncol
18813228
|
16 |
0 |
2008 |
|
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow.
|
Eur Heart J
17353227
|
42 |
20.212 |
2007 |
|
Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
|
Eur Heart J
17984134
|
8 |
20.212 |
2007 |
|
Altered intestinal function in patients with chronic heart failure.
|
J Am Coll Cardiol
17936155
|
199 |
19.896 |
2007 |
|
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
|
J Am Coll Cardiol
17306703
|
47 |
19.896 |
2007 |
|
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
|
J Am Coll Cardiol
17996563
|
42 |
19.896 |
2007 |
|
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.
|
J Am Coll Cardiol
17825714
|
181 |
19.896 |
2007 |
|
Prediction of mode of death in heart failure: the Seattle Heart Failure Model.
|
Circulation
17620506
|
77 |
19.309 |
2007 |
|
Tipping the scale: heart failure, body mass index, and prognosis.
|
Circulation
17679626
|
6 |
19.309 |
2007 |
|
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1.
|
Circ Res
17234973
|
111 |
13.965 |
2007 |
|
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.
|
Diabetes
17327431
|
99 |
8.684 |
2007 |
|
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.
|
Eur J Heart Fail
17481947
|
90 |
6.968 |
2007 |
|
Excessive ventilation during early phase of exercise: a new predictor of poor long-term outcome in patients with chronic heart failure.
|
Eur J Heart Fail
17702647
|
6 |
6.968 |
2007 |
|
Uric acid as a prognostic marker in acute heart failure--new expectations from an old molecule.
|
Eur J Heart Fail
17433888
|
4 |
6.968 |
2007 |
|
Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes.
|
Eur J Heart Fail
17532263
|
5 |
6.968 |
2007 |
|
Nutritional iron deficiency in patients with chronic illnesses.
|
Lancet
18068513
|
2 |
6.594 |
2007 |
|
Inflammatory pathways in patients with heart failure and preserved ejection fraction.
|
Int J Cardiol
17658631
|
22 |
6.189 |
2007 |
|
Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure.
|
Int J Cardiol
17383753
|
33 |
6.189 |
2007 |
|
Neurokinin-1 receptor activation induces reactive oxygen species and epithelial damage in allergic airway inflammation.
|
Clin Exp Allergy
17941913
|
10 |
5.264 |
2007 |
|
Risk factor paradox in wasting diseases.
|
Curr Opin Clin Nutr Metab Care
17563461
|
100 |
4.023 |
2007 |
|
Atrial natriuretic peptide and related peptides.
|
Clin Chem Lab Med
17663625
|
7 |
3.432 |
2007 |
|
How does cachexia influence survival in cancer, heart failure and other chronic diseases?
|
Curr Opin Support Palliat Care
18685379
|
12 |
2.045 |
2007 |
|
["Partnership for the Heart"--development and testing of a new remote patient monitoring system].
|
Dtsch Med Wochenschr
17315125
|
4 |
0.552 |
2007 |
|
Targeting the toll-system in cardiovascular sciences.
|
Recent Pat Inflamm Allergy Drug Discov
19075967
|
1 |
0 |
2007 |
|
Biomarkers for chronic heart failure.
|
Heart Fail Monit
17487296
|
2 |
0 |
2007 |
|
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET.
|
Eur Heart J
16717081
|
54 |
20.212 |
2006 |
|
Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease.
|
Eur Heart J
16891382
|
9 |
20.212 |
2006 |
|
Noninvasive home telemonitoring: the Trans-European Network-Home-Care Management System.
|
J Am Coll Cardiol
16904569
|
1 |
19.896 |
2006 |
|
Questions in cardiac resynchronization therapy: metabolic implications.
|
J Am Coll Cardiol
16875992
|
0 |
19.896 |
2006 |
|
Obesity and the heart a weighty issue.
|
J Am Coll Cardiol
16750695
|
5 |
19.896 |
2006 |
|
Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure.
|
Circulation
16818813
|
46 |
19.309 |
2006 |
|
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival.
|
Circulation
17030678
|
96 |
19.309 |
2006 |
|
The Seattle Heart Failure Model: prediction of survival in heart failure.
|
Circulation
16534009
|
533 |
19.309 |
2006 |
|
Cachexia and cardiology.
|
Circulation
16606798
|
1 |
19.309 |
2006 |
|
Obesity and risk of myocardial infarction: the INTERHEART study.
|
Lancet
16581394
|
1 |
7.554 |
2006 |
|
Post-operative obesity and cachexia after heart transplantation.
|
J Heart Lung Transplant
16507436
|
1 |
7.114 |
2006 |
|
Changes in exercise capacity, ventilation, and body weight following heart transplantation.
|
Eur J Heart Fail
17023206
|
8 |
6.968 |
2006 |
|
Metabolic disturbances in chronic heart failure: a case for the "macho" approach with testosterone?!
|
Eur J Heart Fail
17027336
|
6 |
6.968 |
2006 |
|
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients.
|
Am J Clin Nutr
16469976
|
100 |
6.926 |
2006 |
|
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
|
Int J Cardiol
16846656
|
22 |
6.189 |
2006 |
|
Decompensated heart failure and cachexia: Is it time to legalize anabolics?
|
Int J Cardiol
16828897
|
1 |
6.189 |
2006 |
|
Impact of neurohormonal blockade on association between body mass index and mortality.
|
Int J Cardiol
17052777
|
2 |
6.189 |
2006 |
|
The significance of 123I-BMIPP delayed scintigraphic imaging in cardiac patients.
|
Int J Cardiol
16843549
|
2 |
6.189 |
2006 |
|
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement.
|
Int J Cardiol
17064790
|
30 |
6.189 |
2006 |
|
Uric acid in CHF: marker or player in a metabolic disease?
|
Int J Cardiol
16844250
|
4 |
6.189 |
2006 |
|
Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study.
|
Int J Cardiol
16337039
|
28 |
6.189 |
2006 |
|
Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure.
|
Cardiovasc Res
17034772
|
68 |
5.878 |
2006 |
|
Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links.
|
Cardiovasc Res
16480965
|
32 |
5.878 |
2006 |
|
ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology.
|
Clin Nutr
16697084
|
20 |
4.548 |
2006 |
|
Toll-like receptor modulation in cardiovascular disease: a target for intervention?
|
Expert Opin Investig Drugs
16859390
|
1 |
4.03 |
2006 |
|
Epidemiology of dialysis patients and heart failure patients.
|
Semin Nephrol
16530605
|
23 |
3.598 |
2006 |
|
Metabolic and immunologic derangements in cardiac cachexia: where to from here?
|
Heart Fail Rev
16819578
|
7 |
3.481 |
2006 |
|
Prognostic role of body mass index after acute myocardial infarction.
|
Am J Cardiol
17126669
|
0 |
3.398 |
2006 |
|
Prognosis and therapy approaches of cardiac cachexia.
|
Curr Opin Cardiol
16601462
|
16 |
2.08 |
2006 |
|
Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
|
Cardiology
16960445
|
10 |
1.523 |
2006 |
|
Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease.
|
Intern Med
16880713
|
10 |
0.815 |
2006 |
|
The need for a standardized definition for cachexia in chronic illness.
|
Nat Clin Pract Endocrinol Metab
16932326
|
14 |
0 |
2006 |
|
The roles of immunity and autoimmunity in chronic heart failure.
|
Ernst Schering Res Found Workshop
16329662
|
0 |
0 |
2006 |
|
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure.
|
Eur Heart J
16081469
|
91 |
20.212 |
2005 |
|
Anaemia of chronic disease in chronic heart failure: the emerging evidence.
|
Eur Heart J
16204265
|
1 |
20.212 |
2005 |
|
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.
|
Eur Heart J
15888496
|
33 |
20.212 |
2005 |
|
Heart failure therapy: testosterone replacement and its implications.
|
Eur Heart J
16291772
|
0 |
20.212 |
2005 |
|
The importance of the gastrointestinal system in the pathogenesis of heart failure.
|
Eur Heart J
15980032
|
67 |
20.212 |
2005 |
|
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
|
Eur Heart J
15642700
|
334 |
20.212 |
2005 |
|
The prognostic importance of body mass index after complicated myocardial infarction.
|
J Am Coll Cardiol
15629390
|
15 |
19.896 |
2005 |
|
The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle.
|
J Am Coll Cardiol
16286162
|
62 |
19.896 |
2005 |
|
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
|
J Am Coll Cardiol
16256870
|
52 |
19.896 |
2005 |
|
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure.
|
J Am Coll Cardiol
16168285
|
89 |
19.896 |
2005 |
|
Reversibility of cardiac cachexia after heart transplantation.
|
J Heart Lung Transplant
16297777
|
6 |
7.114 |
2005 |
|
Exercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosis.
|
Eur J Heart Fail
16326362
|
6 |
6.968 |
2005 |
|
Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins.
|
Eur J Heart Fail
15921783
|
12 |
6.968 |
2005 |
|
Cellular endotoxin desensitization in patients with severe chronic heart failure.
|
Eur J Heart Fail
16087139
|
5 |
6.968 |
2005 |
|
Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure.
|
Eur J Heart Fail
16112903
|
6 |
6.968 |
2005 |
|
The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure.
|
Eur J Heart Fail
16337191
|
5 |
6.968 |
2005 |
|
Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases.
|
Int J Cardiol
16242192
|
27 |
6.189 |
2005 |
|
Takotsubo cardiomyopathy.
|
Int J Cardiol
16257463
|
1 |
6.189 |
2005 |
|
Neurohumoral activation as a link to systemic manifestations of chronic lung disease.
|
Chest
16304321
|
58 |
6.147 |
2005 |
|
Anemia and inflammation in COPD.
|
Chest
15764763
|
33 |
6.147 |
2005 |
|
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
|
Heart
15604317
|
6 |
6.059 |
2005 |
|
Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?
|
Heart
15894755
|
16 |
6.059 |
2005 |
|
A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis.
|
J Mol Med (Berl)
15875151
|
21 |
4.686 |
2005 |
|
Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy.
|
J Am Geriatr Soc
16274392
|
2 |
4.388 |
2005 |
|
Future prospects of anticytokine therapy in chronic heart failure.
|
Expert Opin Investig Drugs
15806710
|
6 |
4.03 |
2005 |
|
Pathophysiology of peripheral muscle wasting in cardiac cachexia.
|
Curr Opin Clin Nutr Metab Care
15809526
|
22 |
4.023 |
2005 |
|
Uric acid in chronic heart failure.
|
Semin Nephrol
15660337
|
12 |
3.598 |
2005 |
|
Muscle wasting in cardiac cachexia.
|
Int J Biochem Cell Biol
15927519
|
31 |
3.505 |
2005 |
|
Association of deranged adrenal steroid metabolism with anemia in chronic heart failure.
|
Am J Cardiol
15979444
|
5 |
3.398 |
2005 |
|
Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors.
|
Am J Cardiol
15781025
|
8 |
3.398 |
2005 |
|
Optimizing insulin sensitivity assessment using the minimal model in chronic heart failure.
|
Horm Metab Res
15778928
|
3 |
2.268 |
2005 |
|
Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches.
|
Curr Heart Fail Rep
16332313
|
16 |
0.185 |
2005 |
|
Anemia in chronic heart failure--clinical and prognostic significance.
|
Curr Med Chem Cardiovasc Hematol Agents
16250861
|
0 |
0 |
2005 |
|
Obesity paradox as a component of reverse epidemiology in heart failure.
|
Arch Intern Med
16087835
|
10 |
0 |
2005 |
|
Inflammation, cholesterol levels, and risk of mortality among patients receiving dialysis.
|
JAMA
15100197
|
1 |
44.405 |
2004 |
|
Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial.
|
Eur Heart J
15191772
|
46 |
20.212 |
2004 |
|
B-type natriuretic peptide serum levels in acute heart failure.
|
Eur Heart J
15191781
|
1 |
20.212 |
2004 |
|
Vagal nerve stimulation in chronic heart failure: an antiinflammatory intervention?
|
Circulation
15277335
|
1 |
19.309 |
2004 |
|
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
|
Circulation
15381643
|
79 |
19.309 |
2004 |
|
Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure.
|
Eur J Heart Fail
15182764
|
31 |
6.968 |
2004 |
|
Selective intestinal decontamination in advanced chronic heart failure: a pilot trial.
|
Eur J Heart Fail
15182775
|
26 |
6.968 |
2004 |
|
Efficacy of a homeopathic Crataegus preparation.
|
Eur J Heart Fail
15182781
|
0 |
6.968 |
2004 |
|
Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival.
|
Int J Cardiol
15301893
|
32 |
6.189 |
2004 |
|
Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study.
|
Int J Cardiol
15336800
|
11 |
6.189 |
2004 |
|
Procalcitonin-guided antibiotic treatment in heart failure.
|
Lancet
15135615
|
5 |
6.179 |
2004 |
|
Inflammatory mediators in chronic heart failure: an overview.
|
Heart
15020532
|
168 |
6.059 |
2004 |
|
Cardiac cachexia.
|
Ann Med
15513302
|
45 |
4.323 |
2004 |
|
Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue.
|
J Card Fail
15470653
|
15 |
3.765 |
2004 |
|
Anemia in chronic heart failure: pathogenetic mechanisms.
|
J Card Fail
15007793
|
19 |
3.765 |
2004 |
|
Impact of levosimendan treatment on chronic heart failure.
|
Am J Cardiol
15476643
|
0 |
3.398 |
2004 |
|
Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention.
|
Am J Cardiol
15566934
|
0 |
3.398 |
2004 |
|
Differential contribution of dead space ventilation and low arterial pCO2 to exercise hyperpnea in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
|
Am J Cardiol
14759381
|
14 |
3.398 |
2004 |
|
Statins: a treatment option for chronic heart failure?
|
Heart Fail Monit
15772704
|
2 |
0 |
2004 |
|
Impact of body mass index on outcome in patients after coronary artery bypass grafting with and without valve surgery.
|
Eur Heart J
14585252
|
24 |
20.212 |
2003 |
|
The relationship between cholesterol and survival in patients with chronic heart failure.
|
J Am Coll Cardiol
14662255
|
105 |
19.896 |
2003 |
|
Anemia and congestive heart failure.
|
Circulation
12914015
|
0 |
19.309 |
2003 |
|
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
|
Circulation
12707250
|
143 |
19.309 |
2003 |
|
Myocardial production of C-type natriuretic peptide in chronic heart failure.
|
Circulation
12566368
|
41 |
19.309 |
2003 |
|
Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure.
|
Eur J Heart Fail
14607199
|
59 |
6.968 |
2003 |
|
Anaemia is an independent predictor of poor outcome in patients with chronic heart failure.
|
Int J Cardiol
12957766
|
19 |
6.189 |
2003 |
|
The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure.
|
Int J Cardiol
12957752
|
7 |
6.189 |
2003 |
|
Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia.
|
Int J Cardiol
12821225
|
15 |
6.189 |
2003 |
|
Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications.
|
Basic Res Cardiol
14685702
|
20 |
5.306 |
2003 |
|
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
|
Lancet
12672310
|
182 |
4.902 |
2003 |
|
Growth hormone resistance in chronic heart failure and its therapeutic implications.
|
J Card Fail
12815572
|
17 |
3.765 |
2003 |
|
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity.
|
J Card Fail
12612870
|
63 |
3.765 |
2003 |
|
Statins and the role of nitric oxide in chronic heart failure.
|
Heart Fail Rev
12652163
|
15 |
3.481 |
2003 |
|
Effect of anemia on exercise tolerance in chronic heart failure in men.
|
Am J Cardiol
12667582
|
20 |
3.398 |
2003 |
|
Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease.
|
Am J Cardiol
12860222
|
36 |
3.398 |
2003 |
|
Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern.
|
Am J Cardiol
12745124
|
0 |
3.398 |
2003 |
|
Anemia in chronic heart failure--frequency and prognostic impact.
|
Clin Nephrol
12940540
|
0 |
1.058 |
2003 |
|
Anemia in chronic congestive heart failure: frequency, prognosis, and treatment.
|
Heart Fail Monit
12808478
|
1 |
0 |
2003 |
|
52nd annual scientific sessions of the ACC: highlights in CHF research. March 30-April 2, 2003, Chicago, IL, USA.
|
Heart Fail Monit
14503537
|
0 |
0 |
2003 |
|
Sympathetic activation and malignant ventricular arrhythmias: a molecular link?
|
Eur Heart J
12090743
|
0 |
20.212 |
2002 |
|
Is a high hematocrit level good for patients with heart failure?
|
J Am Coll Cardiol
12020504
|
0 |
19.896 |
2002 |
|
The regulation and measurement of plasma volume in heart failure.
|
J Am Coll Cardiol
12084586
|
36 |
19.896 |
2002 |
|
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.
|
Circulation
12119247
|
106 |
19.309 |
2002 |
|
Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease.
|
Circulation
12093776
|
81 |
19.309 |
2002 |
|
Heat shock proteins and endotoxin combined as a trigger for inflammatory cytokine release during cardiopulmonary bypass: a possible third way?
|
Circulation
12221067
|
0 |
19.309 |
2002 |
|
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
|
Circulation
12045167
|
174 |
19.309 |
2002 |
|
The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty.
|
Int J Cardiol
12036529
|
7 |
6.189 |
2002 |
|
Cytokines, apoptosis and cachexia: the potential for TNF antagonism.
|
Int J Cardiol
12163221
|
28 |
6.189 |
2002 |
|
Cachexia: time to receive more attention.
|
Int J Cardiol
12163204
|
1 |
6.189 |
2002 |
|
Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha.
|
Int J Cardiol
11959387
|
14 |
6.189 |
2002 |
|
Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration.
|
Int J Cardiol
12419560
|
19 |
6.189 |
2002 |
|
Cardiac cachexia in early literature: a review of research prior to Medline.
|
Int J Cardiol
12163205
|
12 |
6.189 |
2002 |
|
Beta-blocker therapy for dynamic left-ventricular outflow tract obstruction.
|
Int J Cardiol
12419557
|
5 |
6.189 |
2002 |
|
The syndrome of cardiac cachexia.
|
Int J Cardiol
12163209
|
86 |
6.189 |
2002 |
|
Cachexia: a therapeutic approach beyond cytokine antagonism.
|
Int J Cardiol
12163222
|
16 |
6.189 |
2002 |
|
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
|
Int J Cardiol
12419548
|
86 |
6.189 |
2002 |
|
PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH.
|
Int J Cardiol
12007680
|
0 |
6.189 |
2002 |
|
The cardiac component of cardiac cachexia.
|
Am Heart J
12094187
|
11 |
4.436 |
2002 |
|
Human pituitary growth hormone and cancer risk.
|
Lancet
12480468
|
0 |
4.33 |
2002 |
|
beta-blockers in heart failure--much more than heart rate reduction.
|
J Card Fail
12528089
|
0 |
3.765 |
2002 |
|
Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.
|
Am J Cardiol
12450603
|
15 |
3.398 |
2002 |
|
Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.
|
Am J Cardiol
12161227
|
16 |
3.398 |
2002 |
|
Immune and neurohormonal pathways in chronic heart failure.
|
Congest Heart Fail
11821625
|
7 |
0 |
2002 |
|
Meeting report from the 74th annual scientific sessions of the American Heart Association (AHA). Anaheim, CA, USA, November 11-14, 2001.
|
Heart Fail Monit
12638577
|
0 |
0 |
2002 |
|
Insulin-like growth factor-I can be helpful towards end of life.
|
BMJ
11291651
|
0 |
20.785 |
2001 |
|
The 6-minute walk test and prognosis in chronic heart failure--the available evidence.
|
Eur Heart J
11237537
|
5 |
20.212 |
2001 |
|
Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight.
|
Eur Heart J
11728148
|
11 |
20.212 |
2001 |
|
The role of C-type natriuretic peptide in cardiovascular medicine.
|
Eur Heart J
11428835
|
6 |
20.212 |
2001 |
|
Preservation of exercise capacity and lack of peripheral changes in asymptomatic patients with severely impaired left ventricular function.
|
Eur Heart J
11207081
|
6 |
20.212 |
2001 |
|
Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.
|
J Am Coll Cardiol
11401115
|
25 |
19.896 |
2001 |
|
Vascular effect of insulin in endothelial dysfunction.
|
J Am Coll Cardiol
11216999
|
0 |
19.896 |
2001 |
|
Lean tissue adjusted peak oxygen consumption in congestive heart failure.
|
J Am Coll Cardiol
11451290
|
3 |
19.896 |
2001 |
|
Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.
|
J Am Coll Cardiol
11499736
|
38 |
19.896 |
2001 |
|
Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis.
|
Circulation
11181471
|
65 |
19.309 |
2001 |
|
Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure.
|
Circulation
11479251
|
98 |
19.309 |
2001 |
|
Wasting as an independent predictor of mortality in patients with cystic fibrosis.
|
Thorax
11562511
|
60 |
8.272 |
2001 |
|
First Cachexia Symposium, Berlin, Germany, 1st-2nd December, 2000.
|
Eur J Heart Fail
11738229
|
1 |
6.968 |
2001 |
|
Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure.
|
Int J Cardiol
11104867
|
32 |
6.189 |
2001 |
|
The significance of leptin in human--do we know it yet?
|
Int J Cardiol
11104866
|
0 |
6.189 |
2001 |
|
Raised urinary glucocorticoid and adrenal androgen precursors in the urine of young hypertensive patients: possible evidence for partial glucocorticoid resistance.
|
Heart
11454825
|
2 |
6.059 |
2001 |
|
Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin.
|
Cardiovasc Res
11476740
|
21 |
5.878 |
2001 |
|
Chronic heart failure in the very elderly: clinical status, survival, and prognostic factors in 188 patients more than 70 years old.
|
Am Heart J
11431675
|
10 |
4.436 |
2001 |
|
Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.
|
Am Heart J
11320368
|
15 |
4.436 |
2001 |
|
Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia.
|
Eur J Endocrinol
11720897
|
26 |
4.101 |
2001 |
|
High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients.
|
Cytokine
11500083
|
21 |
3.488 |
2001 |
|
Antiendotoxin antibody levels in unstable angina: lessons from chronic heart failure and cardiopulmonary bypass.
|
Am J Cardiol
11703981
|
0 |
3.398 |
2001 |
|
[Tumor necrosis factor alpha in chronic heart failure. Clinical manifestation and therapeutic possibilities].
|
Herz
11765476
|
2 |
0.776 |
2001 |
|
The importance of tumor necrosis factor and lipoproteins in the pathogenesis of chronic heart failure.
|
Heart Fail Monit
12634890
|
1 |
0 |
2001 |
|
Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure.
|
Eur Heart J
10637088
|
14 |
20.212 |
2000 |
|
TNF-alpha system in CHF.
|
Eur Heart J
10739736
|
0 |
20.212 |
2000 |
|
Non-invasive assessment of vascular function; paradoxical vascular response to intravenous glucose in coronary heart disease.
|
Eur Heart J
10610742
|
1 |
20.212 |
2000 |
|
Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2).
|
Eur Heart J
10637089
|
123 |
20.212 |
2000 |
|
Plasma concentrations of bacterial lipopolysaccharide: a marker of infection or inflammation?
|
J Am Coll Cardiol
10933386
|
3 |
19.896 |
2000 |
|
The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
|
J Am Coll Cardiol
10933367
|
15 |
19.896 |
2000 |
|
Plasma cytokine parameters and mortality in patients with chronic heart failure.
|
Circulation
11120695
|
201 |
19.309 |
2000 |
|
Defects in insulin action in chronic heart failure.
|
Diabetes Obes Metab
11225653
|
1 |
6.715 |
2000 |
|
Superiority of endothelin-1 over norepinephrine in exercise-induced alterations of the conduit artery tone of the non-exercised arm in patients with chronic heart failure.
|
Int J Cardiol
10748306
|
3 |
6.189 |
2000 |
|
The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1.
|
Int J Cardiol
10646959
|
29 |
6.189 |
2000 |
|
Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.
|
Drugs
11152010
|
16 |
5 |
2000 |
|
Relation of changes over time in ventricular size and function to those in exercise capacity in patients with chronic heart failure.
|
Am Heart J
10783227
|
2 |
4.436 |
2000 |
|
The endotoxin-lipoprotein hypothesis.
|
Lancet
11036910
|
117 |
4.249 |
2000 |
|
Insulin-mediated glucose uptake in congestive heart failure.
|
Am J Cardiol
11078259
|
0 |
3.398 |
2000 |
|
Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure.
|
Am J Cardiol
10913476
|
3 |
3.398 |
2000 |
|
Insulin resistance in chronic heart failure.
|
J Cardiovasc Pharmacol
11346220
|
20 |
2.247 |
2000 |
|
Chronic heart failure as a metabolic disorder.
|
Heart Fail Monit
12634873
|
1 |
0 |
2000 |
|
Endotoxin and immune activation in chronic heart failure: a prospective cohort study.
|
Lancet
10359409
|
188 |
47.831 |
1999 |
|
The impact of cachexia on cardiorespiratory reflex control in chronic heart failure.
|
Eur Heart J
10543930
|
10 |
20.212 |
1999 |
|
Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure.
|
Eur Heart J
10208789
|
80 |
20.212 |
1999 |
|
Peak VO2 et al. for prognosis in heart failure?
|
J Am Coll Cardiol
9973047
|
1 |
19.896 |
1999 |
|
Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity.
|
Circulation
10595954
|
50 |
19.309 |
1999 |
|
Heart failure as a metabolic problem.
|
Eur J Heart Fail
10937921
|
2 |
6.968 |
1999 |
|
Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation.
|
Int J Cardiol
10636626
|
29 |
6.189 |
1999 |
|
Cardiac cachexia is a world-wide problem.
|
Int J Cardiol
10574394
|
4 |
6.189 |
1999 |
|
Three year mortality in heart failure patients with very low left ventricular ejection fractions.
|
Int J Cardiol
10501338
|
10 |
6.189 |
1999 |
|
Intraventricular conduction delay: a prognostic marker in chronic heart failure.
|
Int J Cardiol
10454306
|
50 |
6.189 |
1999 |
|
Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.
|
Chest
10084500
|
67 |
6.147 |
1999 |
|
Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure.
|
Heart
10455087
|
1 |
6.059 |
1999 |
|
Loss of bone mineral in patients with cachexia due to chronic heart failure.
|
Am J Cardiol
10073875
|
18 |
3.398 |
1999 |
|
Insulin-mediated glucose uptake in congestive heart failure.
|
Am J Cardiol
10498157
|
0 |
3.398 |
1999 |
|
Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease.
|
Am J Cardiol
10073796
|
4 |
3.398 |
1999 |
|
Insights into the pathogenesis of chronic heart failure: immune activation and cachexia.
|
Curr Opin Cardiol
10358792
|
20 |
2.08 |
1999 |
|
Chronic heart failure and cardiac cachexia and links between the endocrine and immune systems.
|
Z Kardiol
27320305
|
0 |
0 |
1999 |
|
Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
|
Lancet
9643742
|
44 |
47.831 |
1998 |
|
Uric acid in chronic heart failure: a marker of chronic inflammation.
|
Eur Heart J
9886724
|
62 |
20.212 |
1998 |
|
Catecholamine levels and treatment in chronic heart failure.
|
Eur Heart J
9651737
|
5 |
20.212 |
1998 |
|
Growth hormone treatment in chronic heart failure: lessons from the first 99 patients.
|
Eur Heart J
9857911
|
0 |
20.212 |
1998 |
|
Cachexia in heart failure is bad for you.
|
Eur Heart J
9519307
|
1 |
20.212 |
1998 |
|
Hyperleptinaemia in chronic heart failure. Relationships with insulin.
|
Eur Heart J
9820994
|
22 |
20.212 |
1998 |
|
Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation.
|
J Am Coll Cardiol
9708466
|
40 |
19.896 |
1998 |
|
Uric acid in chronic heart failure: a measure of the anaerobic threshold.
|
Metabolism
9751248
|
7 |
5.777 |
1998 |
|
Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure.
|
Am J Cardiol
9708664
|
17 |
3.398 |
1998 |
|
Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure.
|
QJM
9604072
|
8 |
3.131 |
1998 |
|
Wasting as independent risk factor for mortality in chronic heart failure.
|
Lancet
9107242
|
317 |
47.831 |
1997 |
|
Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex.
|
Eur Heart J
9076386
|
41 |
20.212 |
1997 |
|
The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure.
|
Eur Heart J
9043843
|
34 |
20.212 |
1997 |
|
Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.
|
J Am Coll Cardiol
9247528
|
120 |
19.896 |
1997 |
|
Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting.
|
J Am Coll Cardiol
9316530
|
38 |
19.896 |
1997 |
|
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure.
|
J Am Coll Cardiol
9180123
|
93 |
19.896 |
1997 |
|
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure.
|
J Am Coll Cardiol
9385904
|
117 |
19.896 |
1997 |
|
Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure.
|
Circulation
9355898
|
68 |
19.309 |
1997 |
|
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.
|
Circulation
9244221
|
152 |
19.309 |
1997 |
|
Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction.
|
Circulation
9008480
|
2 |
19.309 |
1997 |
|
Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure.
|
Heart
9290400
|
14 |
6.059 |
1997 |
|
Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
|
Am J Cardiol
9202356
|
108 |
3.398 |
1997 |
|
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure.
|
Am J Cardiol
9165177
|
72 |
3.398 |
1997 |
|
Effect of reduced muscle bulk on the ventilatory response to exercise in chronic congestive heart failure secondary to idiopathic dilated and ischemic cardiomyopathy.
|
Am J Cardiol
9205030
|
2 |
3.398 |
1997 |
|
Metabolic, functional, and haemodynamic staging for CHF?
|
Lancet
8950874
|
6 |
47.831 |
1996 |
|
Heart rhythms, ventricular arrhythmias, and death in chronic heart failure.
|
J Card Fail
8891855
|
6 |
3.765 |
1996 |
|
Inspiratory muscle strength is a determinant of maximum oxygen consumption in chronic heart failure.
|
Br Heart J
7488451
|
14 |
0 |
1995 |
